Virus-like particle mediated circular RNA delivery
By integrating recruited RNA motifs into polynucleotides and packaging them with virus-like particles, the problem of delivery of circRNAs is solved, and the stability and long-term effects are improved, and the stability and efficiency in existing RNA vaccines and treatments are solved. question.
Patent Information
- Application Number
- CN202380035919.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-24
- Filing Date
- 2023-02-17
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively deliver bioactive circular RNA (circRNA) to target cells, and the short half-life and ease of degradation of RNA make it difficult to last long-term therapeutic effects, affecting the stability and efficiency of RNA-based vaccines and treatment methods.
By integrating the recruited RNA motif into the polynucleotide to be packaged, a linear polynucleotide that can be cyclized is formed, and circRNAs are packaged and delivered using virus-like particles (VLPs), and the capsid protein and RNA binding structure of the virus-like particles are used to bind to RNA. Domain interactions enable stable packaging and delivery of circRNAs.
Improves the stability and delivery efficiency of circRNAs, extends the duration of therapeutic effects, and enhances the stability and safety of RNA-based vaccines and treatments.
Smart Images

Figure BDA0005098332220000181 
Figure BDA0005098332220000191 
Figure BDA0005098332220000201
Abstract
Description
Technical Field
[0001] The present invention relates to virus-like particles (VLPs), which include artificial circular RNA molecules containing RNA elements of interest. The present invention also relates to methods for producing virus-like particles (VLPs), which include artificial circular RNA molecules containing RNA elements of interest. Background Art
[0002] RNA is used for therapeutic interventions through different mechanistic pathways. There are methods to inhibit the expression of genes (e.g., through the application of siRNA or antisense RNA), but there are also various technologies to induce gene expression through the application of therapeutically active RNA, as is currently being successfully used in the clinic for almost countless vaccinations against the SARS-CoV-2 virus by inducing the expression of the SARS-CoV-2 spike protein.
[0003] Compared to therapeutic treatments with DNA, RNA applications have the great advantage that the effects obtained are short-lived and do not cause any modifications to the chromosomal DNA, thus preventing potentially harmful long-term consequences. Since RNA has a rather short half-life and cannot be incorporated into chromosomal DNA, this negative effect can be completely ignored. However, a disadvantage is that RNA-mediated effects occur only for a few days, which seems to be at least sufficient to initiate an immune response to new viral threats. Since RNases are highly efficient at degrading RNA molecules in a rather short time, it is difficult to achieve long-term sustained effects and repeated applications of RNA-based treatments are required.
[0004] One way to improve the stability of therapeutically active RNA transcripts is through the use of circular RNA (circRNA), which is a covalently closed single-stranded RNA molecule that can be generated in eukaryotic cells by a non-classical RNA splicing mechanism called backsplicing. Initially, circRNAs were thought to play a role mainly in viruses (e.g., hepatitis delta virus or plant viroids), but in the meantime, circRNAs have been found in fungi, plants, insects, fish, and mammals - this is supported by next-generation sequencing of RNA in high-throughput methods.
[0005] Unlike linear mRNA, circular RNA (circRNA) is highly stable because its covalently closed ring structure protects it from exonuclease-mediated degradation. New possibilities for therapeutic intervention are currently being investigated in detail.
[0006] So far, a major obstacle for circRNA-based therapies has been the delivery of biologically active circRNA molecules with sufficiently high efficiency into the correct cells and, therefore, into the appropriate organs. In particular, the in vivo delivery of circRNAs is problematic, but in vitro approaches (e.g., modification of T cells for CAR-T cell therapy) would also benefit significantly if the delivery of circRNAs could be improved while keeping cytotoxic effects at tolerable levels.
[0007] Delivery of linear single-stranded RNA is made possible by lipid nanoparticle encapsulation. Recently, the clinical utility of mRNA vaccines delivered with lipid nanoparticles has been highlighted by their use in SARS-CoV-2 vaccines from Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2). Lipid nanoparticles must fulfill multiple functions: (i) once the RNA drug is administered, they must protect the cargo from nucleases in physiological fluids, (ii) they should be modified to escape the mononuclear phagocyte system (MPS) and be cleared by glomerular filtration, especially when administered systemically, (iii) they should be able to enter target cells efficiently, and (iv) once internalized, they need to escape from endosomes. In order to achieve these tasks with maximum efficiency, many chemical modifications have been studied and their respective advantages and disadvantages have been proposed. For this reason, current mRNA vaccines still have certain limitations due to their inherent instability and suboptimal thermal stability for in vivo administration after encapsulation, as well as potential immunogenic side effects. Lipid nanoparticles encapsulating RNA are very complex systems. Disadvantages include the presence of alternative colloidal structures, the complexity of the physical state of the lipids, and the possibility of supercooled melts causing stability problems during storage or administration. Sample dilution or removal of water can significantly change the physical state of the lipids and the equilibrium between the different colloidal species.
[0008] Recently, circRNA vaccines against SARS-CoV-2 and circRNAs expressing nanoantibodies or AEC2 decoys to neutralize SARS-CoV-2 have been developed (Liang Qu et al. (2021): Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants. doi: https: / / doi.org / 10.1101 / 2021.03.16.435594). These circRNAs are also delivered via lipid nanoparticle encapsulation. The limitations of this packaging approach have been described above for linear RNAs and also apply to circular RNAs.
[0009] Therefore, there is an unmet need for the production of new safe and efficient vectors for the delivery of genetic material in a subject (eg, a mammal).
[0010] However, over millions of years, viruses have evolved strategies to identify pathways that effectively enter the cytoplasm of target cells. The inventors unexpectedly found that circRNAs can be packaged into virus-like particles (VLPs). By integrating the recruiting RNA motif into the molecule to be packaged, circRNAs (e.g., coding or non-coding circRNAs) can be selectively packaged into VLPs. The recruiting RNA motif can only play a role through cyclization, whereby the molecule to be packaged is packaged only with its cyclized state. Unexpectedly, these RNAs can also be packaged in the envelope of DNA viruses. These VLPs can be used for the in vivo or in vitro delivery of (therapeutic) circRNA molecules. Summary of the invention
[0011] In a first aspect, the present invention relates to a (linear) polynucleotide (capable of circularization) comprising, from 5' to 3', in the following order:
[0012] The first back-splicing intron sequence,
[0013] The first part of the recruiting RNA motif,
[0014] The nucleotide sequence of interest,
[0015] recruits the second part of the RNA motif, and
[0016] The second back-splicing intron sequence,
[0017] Wherein, the first part of the recruiting RNA motif and the second part of the recruiting RNA motif form a functional recruiting RNA motif after cyclization.
[0018] In a second aspect, the present invention relates to a vector comprising the polynucleotide of the first aspect.
[0019] In a third aspect, the present invention relates to an artificial circular RNA molecule, comprising an RNA element of interest and a recruiting RNA motif.
[0020] In a fourth aspect, the present invention relates to a compound comprising or involving:
[0021] (i) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, and
[0022] (ii) an artificial circular RNA molecule comprising an RNA element of interest, preferably an artificial circular RNA molecule according to the third aspect.
[0023] In a fifth aspect, the present invention relates to a virus-like particle (VLP) comprising the complex according to the fourth aspect.
[0024] In a sixth aspect, the present invention relates to a virus-like particle (VLP) comprising an artificial circular RNA molecule comprising an RNA element of interest.
[0025] In a seventh aspect, the present invention relates to a method for producing a virus-like particle (VLP), the virus-like particle comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in the fifth aspect or the sixth aspect, the method comprising the following steps:
[0026] (i) providing cells, and
[0027] (ii) introducing the following into a cell, thereby producing a virus-like particle (VLP), wherein the virus-like particle includes an artificial circular RNA molecule comprising an RNA element of interest:
[0028] (iia) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide, and
[0029] (iib) the polynucleotide according to the first aspect, the vector according to the second aspect, the artificial circular RNA molecule comprising an RNA element of interest, or the artificial circular RNA molecule according to the third aspect.
[0030] In an eighth aspect, the present invention relates to a method for producing a virus-like particle (VLP), the virus-like particle comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in the fifth aspect or the sixth aspect, the method comprising the following steps:
[0031] (i) providing a virus-like particle (VLP), wherein the virus-like particle comprises a polypeptide, wherein the polypeptide comprises a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain,
[0032] (ii) disassembling the VLPs,
[0033] (iii) adding an artificial circular RNA molecule comprising an RNA element of interest or an artificial circular RNA molecule according to the third aspect,
[0034] (iv) reassembling the disassembled VLPs,
[0035] Virus-like particles (VLPs) are thereby produced, which include artificial circular RNA molecules comprising the RNA element of interest.
[0036] In a ninth aspect, the present invention relates to a virus-like particle (VLP) obtainable by the method according to the seventh aspect or the eighth aspect.
[0037] In a tenth aspect, the present invention relates to a composition comprising the virus-like particle according to the fifth aspect, the sixth aspect or the ninth aspect.
[0038] In an eleventh aspect, the present invention relates to a virus-like particle according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in medicine.
[0039] In a twelfth aspect, the invention relates to a virus-like particle according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in therapy.
[0040] In a thirteenth aspect, the present invention relates to a virus-like particle according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in vaccination.
[0041] This summary of the invention does not describe all features of the invention. DETAILED DESCRIPTION
[0042] definition
[0043] Before describing the present invention in detail below, it should be understood that the present invention is not limited to the specific methodology, scheme and reagent described herein, because they can change. It should also be understood that the terms used herein are only used for the purpose of describing specific embodiments, and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art.
[0044] Preferably, according to "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and The terms used herein are defined as described in , H. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland.
[0045] Several documents are quoted in the text of this specification in full. No matter above or below, each document quoted herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, sequence submission GenBank accession numbers, etc.) is incorporated herein by reference in its entirety. Any content of this article should not be interpreted as admitting that the present invention is not entitled to be disclosed prior to such disclosure by means of prior invention.
[0046] In the following, the elements of the present invention will be described. These elements are listed together with specific embodiments; however, it should be understood that they can be combined in any manner and in any number to create additional embodiments. The various described embodiments and preferred embodiments should not be interpreted as limiting the present invention to only the embodiments explicitly described. This description should be understood to support and cover embodiments that combine the explicitly described embodiments with any number of disclosed and / or preferred elements. In addition, unless the context indicates otherwise, any arrangement and combination of all described elements in this application should be deemed to be disclosed by the description of this application.
[0047] In this specification and the claims that follow, unless the context requires otherwise, the term "comprise" and variations (e.g., "comprises" and "comprising") will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps. As used in this specification and the claims that follow, the singular forms "a, an, and the" include plural referents unless the content clearly dictates otherwise.
[0048] As used herein, the term "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. In other words, as used herein, the term "consisting essentially of" is generally understood to mean that a composition or formulation (a) must include the listed components, and (b) is open to unlisted components that do not materially affect the basic and novel characteristics of the composition. Similarly, when "consisting essentially of" is used herein in a method claim, the claim requires the listed steps to be performed, but may also include unlisted steps that do not affect the basic and essential characteristics of the method.
[0049] When used in conjunction with a numerical value, the term "about" means encompassing the numerical value within a range having a lower limit that is 5% less than the indicated numerical value and an upper limit that is 5% greater than the indicated numerical value.
[0050] The terms "polypeptide" and "protein" are used interchangeably in the context of the present invention and refer to long peptide-linked chains of amino acids.
[0051] As used herein, the term "polypeptide fragment" or "protein fragment" refers to a polypeptide or protein having a deletion (eg, an amino-terminal deletion and / or a carboxyl-terminal deletion and / or an internal deletion) compared to the full-length polypeptide or protein.
[0052] As used herein, the term "virus" refers to a molecule that replicates only within the living cells of other organisms. It can also be cultured in cell culture. Viruses can infect all types of life forms, from animals and plants to microorganisms (including bacteria and archaea). Although viruses are not in infected cells or in the process of infecting cells, they exist in the form of independent particles. These virus particles, also known as virions, consist of two or three parts: (i) genetic material, which is composed of DNA or RNA (long nucleotides that carry genetic information), (ii) a protein shell, which is called a capsid, which surrounds and protects the genetic material, and in some cases (iii) a lipid envelope, which surrounds the protein shell when it is outside the cell. The shapes of these virus particles range from simple spiral and icosahedral forms of some virus species to more complex structures of other virus species. Therefore, as used herein, the term "virus" also encompasses virus particles.
[0053] As described herein, a virus can be an RNA virus or a DNA virus.
[0054] Preferably,
[0055] a DNA virus selected from the group consisting of papovavirus, papillomavirus, polyomavirus, adenovirus and parvovirus virus, or
[0056] RNA viruses are retroviruses, noroviruses or orthomyxoviruses.
[0057] More preferably,
[0058] The polyomavirus is Simian Virus 40 (SV40), BK virus (BKV), JC virus (JCV) or MPy virus (MPyV),
[0059] Parvovirus is adeno-associated virus (AAV),
[0060] Retroviruses are slow viruses.
[0061] Norovirus is Norwalk virus, or
[0062] Orthomyxoviruses are either influenza A virus or influenza B virus.
[0063] As used herein, the term "enveloped virus" refers to a virus with a viral envelope covering its protective protein capsid. The envelope is usually derived from a portion of the host cell membrane (phospholipids and proteins), but includes some (viral) sugar structures (e.g., glycoproteins and / or sugar oligopeptides). Functionally, the viral envelope helps the virus enter the host cell and can help them avoid the host immune system. The (viral) sugar structure (e.g., glycoproteins and / or sugar oligopeptides) on the envelope surface is used to recognize and bind to receptor sites on the host's membrane. Then, the viral envelope fuses with the host's membrane, allowing the capsid and viral genome to enter and infect the host.
[0064] As used herein, the term "virus-like particle (VLP)" refers to a virus-like structure composed of one or more capsid proteins, which has the ability to self-assemble and mimics the form and size of a virus, but lacks functional genetic material and is therefore unable to establish a productive infection cycle (including the formation of progeny) in host cells.
[0065] As described herein, a virus-like particle (VLP) can be a virus-like particle of an RNA virus or a DNA virus.
[0066] Preferably,
[0067] The virus-like particles of a DNA virus are selected from the group consisting of papovavirus-like particles, papillomavirus-like particles, polyomavirus-like particles, adenovirus-like particles and parvovirus-like particles, or
[0068] The virus-like particles of RNA viruses are retrovirus-like particles, norovirus-like particles or orthomyxovirus-like particles.
[0069] More preferably,
[0070] The polyomavirus-like particle is a simian virus 40 (SV40)-like particle, a BK virus (BKV)-like particle, a JC virus (JCV)-like particle or a MPy virus (MPyV)-like particle,
[0071] Parvovirus-like particles are adeno-associated virus (AAV)-like particles.
[0072] Retrovirus-like particles are lentivirus-like particles.
[0073] Norovirus-like particles are Norwalk virus-like particles, or
[0074] The orthomyxovirus-like particle is an influenza A virus-like particle or an influenza B virus-like particle.
[0075] As used herein, the term "capsid" refers to the protein shell of a virus. It is composed of multiple oligomeric (repeating) structural subunits, which are composed of proteins called protomers. The observable three-dimensional morphological subunits (which may or may not correspond to a single protein) are called capsid particles. The proteins that constitute the capsid of the virus are called "capsid proteins". Alternatively, they are called "viral coat proteins (VCP)".
[0076] As used herein, the term "capsid protein" refers to the protein constituting the capsid of a virus. Therefore, the function of the capsid protein is the formation of the capsid of a virus. Specifically, when one or more genes encoding the production of capsid protein are provided, the capsid protein can be induced to self-assemble into virus-like particles (VLPs), thereby achieving a sufficiently high concentration of capsid protein in a given volume. Capsid protein may need to be processed for self-assembly. Processing (e.g., proteolytic processing) can be achieved by co-expression of a processing enzyme (e.g., protease) or by inserting an artificial (new) processing site into a capsid protein sequence. Artificial (new) processing site can include a target site or self-processing site (e.g., ribosome jump site (e.g., F2A (or 2A-like sequence) of foot-and-mouth disease virus (FMDV)) of a capsid or viral protease.
[0077] The term "fragment of a capsid protein having the function of a capsid protein" refers to a fragment derived from a naturally occurring capsid protein, which lacks one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids) compared to the naturally occurring capsid protein, and has the function of a capsid protein. In particular, the fragment of the naturally occurring capsid protein is still able to constitute / form the capsid of the virus, or is still able to promote the formation / formation of the capsid of the virus. Typically, a fragment of an amino acid sequence includes fewer amino acids than the corresponding full-length sequence, wherein the amino acid sequence present is the same as the continuous order in the full-length sequence. In this regard, a fragment does not include any internal insertion or deletion into the portion of the full-length sequence represented by the fragment.
[0078] The term "derivative of a capsid protein having a capsid protein function" refers to a derivative of a naturally occurring capsid protein, wherein one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids) are replaced, deleted and / or added compared to a naturally occurring capsid protein, and have a capsid protein function. In particular, the derivative of the naturally occurring capsid protein is still able to constitute / form a viral capsid, or is still able to promote the formation / formation of a viral capsid. Compared to a fragment, a derivative may include internal insertions or deletions within the amino acids corresponding to the full-length sequence, or may have similarity to the full-length coding sequence.
[0079] Fragments or derivatives described herein may also be referred to as variants.
[0080] Preferably, the capsid protein has an amino acid sequence according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto. Alternatively, the capsid protein has an amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0081] Capsid proteins having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequence according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4 can be referred to as capsid protein variants. Such capsid protein variants are still able to constitute / form the capsid of the virus, or are still able to promote the formation / formation of the capsid of the virus. For example, the experimental part provides sufficient information in this regard. The same applies to SEQ ID NO: 31 variants.
[0082] As described herein, the capsid protein of a virus or a fragment or derivative thereof having the function of a capsid protein is connected / fused / bound to at least one RNA binding domain. As used herein, the term "RNA binding domain (also referred to as aptamer binding protein (ABP)" refers to a structure (e.g., a peptide or polypeptide / protein) that is capable of binding to a recruiting RNA motif (also referred to as an aptamer). RNA binding peptides or polypeptides / proteins exhibit highly specific recognition of their RNA targets by recognizing their sequence and structure. The specific binding of RNA binding peptides or polypeptides / proteins enables them to distinguish their targets and regulate various cellular functions by controlling the production, maturation, and life cycle of RNA transcripts.
[0083] Specifically, as used herein, the term "RNA binding domain (also referred to as aptamer binding protein (ABP)" refers to one half of a binding pair that is connected / fused / bound to a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and is used to bind / contact an RNA element of interest with a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein by binding to the other half of the binding pair (a recruiting RNA motif (i.e., a "corresponding motif"), which is part of a circular RNA (circRNA) molecule comprising the RNA element of interest).
[0084] Preferably, at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu phage COM RNA binding protein or its RNA binding portion and PP7 coat protein or its RNA binding portion.
[0085] The viral capsid protein or a fragment or derivative thereof having the function of a capsid protein can be connected / fused / bound to at least one RNA binding domain via a linker.
[0086] As used herein, the term "linker" refers to any structure that allows the viral capsid protein or its fragment or derivative with capsid protein function to be connected to at least one RNA binding domain. The term "linker" includes, but is not limited to, chemical modification, peptide linkers, chemical linkers, covalent bonds or non-covalent bonds. Preferably, the linker is covalent. More preferably, the linker is a flexible peptide linker having a sequence consisting mainly of an extension of glycine and serine residues, but may contain additional amino acids (e.g., threonine and alanine) to maintain flexibility, and polar amino acids (e.g., lysine and glutamic acid) to improve solubility. The viral capsid protein or its fragment or derivative with capsid protein function and the RNA binding domain may also exist in the form of protein fusion.
[0087] As used herein, the term "circular RNA (circRNA) molecule" refers to a single-stranded RNA that, unlike linear RNA, forms a covalently closed continuous loop. Specifically, in circular RNA, the 5' end and 3' end that are usually present in RNA molecules have been connected together. Circular RNA (circRNA) molecules can be produced by non-sequential back splicing, in which the downstream splicing donor is connected to the upstream splicing acceptor. Because circular RNA does not have a 5' end and a 3' end, it is resistant to exonuclease-mediated degradation and is more stable than most linear RNAs in cells.
[0088] In nature, the biogenesis of circRNAs is mainly regulated by three different mechanisms: intron pairing-driven circularization, RNA-binding protein (RBPs)-mediated circularization, and lariat-driven circularization. CircRNAs can sequester and recruit miRNAs to regulate the function of miRNAs. CircRNAs also interact with proteins and thus regulate their cellular localization and activity. CircRNAs promote the transcription of their parental genes by interacting with RNA polymerase II (Pol II) or U1 small nuclear ribonucleoprotein (snRNP). CircRNAs play an important role in gene regulation by competing with the classical splicing of pre-mRNAs. Interestingly, some circRNAs are able to encode proteins.
[0089] As described herein, a circular RNA (circRNA) molecule can be part of / can be included in a virus-like particle (VLP). In particular, as described herein, a circular RNA (circRNA) molecule can be packaged into a virus-like particle (VLP). Specifically, it is an artificial circular RNA (circRNA) molecule.
[0090] As described herein, a circular RNA (circRNA) molecule specifically comprises an RNA element of interest and / or a recruiting RNA motif. The recruiting RNA motif binds / is capable of binding to at least one RNA binding domain, which is connected / fused / linked to a viral capsid protein or a fragment thereof having a capsid protein function or a derivative thereof.
[0091] As used herein, the term "recruit, recruiting or recruitment" refers to attracting an element to another structure (e.g., using RNA-peptide or RNA-polypeptide / protein interactions). In this case, the RNA element of interest is recruited by the interaction of the recruiting RNA motif with the RNA binding domain of the capsid protein of the virus, and thus, as described herein, a circular RNA (circRNA) molecule containing the RNA element of interest can be encapsidated / encapsulated within the capsid of a virus-like particle (VLP).
[0092] As used herein, the term "recruiting RNA motif (also referred to as aptamer)" refers to an element that exhibits high selectivity and specific affinity for a given ligand or target. At the molecular level, the recruiting RNA motif / aptamer-ligand or recruiting RNA motif / aptamer-target interactions are particularly mediated by non-covalent forces (e.g., electrostatic interactions, hydrophobic interactions, π-π orbital stacking, and / or hydrogen bonding interactions).
[0093] In particular, as used herein, the term "recruiting RNA motif (also called aptamer)" refers to a short single-stranded RNA oligonucleotide (eg, 25 to 70 bases) that can bind to a specific ligand or target through its 3D structure.
[0094] Specifically, as used herein, the term "recruiting RNA motif (also referred to as an aptamer)" refers to one half of a binding pair, which is used to recruit an RNA element of interest (to which the recruitment motif binds) to a capsid protein, which is connected / fused / linked to the other half of the binding pair, i.e., an RNA binding domain (i.e., a "corresponding motif"). The recruitment RNA motif binds to the RNA binding domain, and in this way the RNA element of interest is recruited to the capsid protein of the virus or a fragment or derivative thereof having a capsid protein function. In other words, in this way, the recruitment RNA motif causes the connection between the RNA element of interest and the capsid protein of the virus or a fragment or derivative thereof having a capsid protein function, allowing the encapsidation / encapsulation of a circular RNA (circRNA) molecule of an RNA element of interest in the capsid protein structure of a virus-like particle (VLP).
[0095] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0096] The RNA binding domain and the recruiting RNA motif can be a pair selected from the above group. More preferably,
[0097] (i) at least one RNA binding domain is an MS2 coat protein or an RNA binding region thereof, and the recruiting RNA motif is an MS2 bacteriophage operator stem-loop,
[0098] (ii) at least one RNA binding domain is a Ku protein or an RNA binding region thereof, and the recruiting RNA motif is a telomerase Ku binding motif,
[0099] (iii) at least one RNA binding domain is a Sm7 protein or an RNA binding region thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif,
[0100] (iv) at least one RNA binding domain is a SfMu bacteriophage COM RNA binding protein or an RNA binding region thereof, and the recruiting RNA motif is a SfMu bacteriophage COM stem-loop, and / or
[0101] (v) at least one RNA binding domain is a PP7 coat protein or an RNA binding region thereof, and the recruiting RNA motif is a PP7 bacteriophage operator stem-loop.
[0102] For example, the coat protein of the RNA bacteriophage MS2 usually binds to the specific MS2 phage operator stem-loop structure in the viral RNA, while the coat protein of the RNA bacteriophage SfMu usually binds to the specific SfMu phage operator stem-loop structure in the viral RNA to complete the encapsidation of the genome and the translation repression of the replicase synthesis.
[0103] In addition, the Ku protein normally binds to TLC1, the RNA component of telomerase. When Ku's ability to bind TLC1 is disrupted, DNA repair through telomere healing is reduced.
[0104] Furthermore, in Saccharomyces cerevisiae, the telomerase RNA TLC1 is normally associated with the Sm7 protein complex, which is required for the stabilization of the major non-polyadenylated (poly(A)-) TLC1 isoform.
[0105] The inventors have used the above-mentioned molecules in their RNA delivery methods.
[0106] As used herein, the term "RNA element of interest" refers to an RNA sequence. The RNA element of interest has a specific function or has a specific purpose and is therefore of interest. The function of the RNA element of interest is, for example, inhibition of gene expression (e.g., by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (e.g., to elicit an immune response). In a prominent example, expression of the spike protein of SARS-CoV-2 is induced to elicit an immune response against the SARS-CoV-2 virus.
[0107] The problem with RNA-based therapeutics so far has been to deliver the bioactive RNA molecules with sufficiently high efficiency into the correct cells, and thereby into the appropriate organs. In particular, the delivery of RNA in vivo is problematic, but in vitro approaches would also benefit greatly if the delivery of RNA could be improved while keeping cytotoxic effects at tolerable levels. Since RNases are highly efficient at degrading RNA molecules in a relatively short period of time, it is difficult to achieve long-term sustained effects and repeated applications of RNA-based therapeutics are required. A delivery mechanism that prevents degradation of bioactive RNA molecules would be highly desirable.
[0108] The object of the present invention is to encapsidate / encapsulate the RNA element of interest in a virus-like particle (VLP) as described herein, particularly in the capsid protein structure of a virus-like particle (VLP) as described herein. In this way, the RNA element of interest is safely packaged and can be effectively delivered to a target cell (e.g., by a viral approach). Since the RNA element of interest is a part of a circular RNA (circRNA) molecule, the molecule is a highly stable and covalently closed circular structure, and therefore can be further protected from exonuclease-mediated degradation.
[0109] Preferably, the RNA element of interest is selected from the group consisting of coding RNA or non-coding RNA. More preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest in the form of protein-coding RNA. The product of interest can be a protein of interest. The RNA of interest can also be a non-coding RNA (e.g., miRNA). Non-coding RNAs are generally used to silence the corresponding target gene.
[0110] As used herein, the term "heterologous RNA element of interest" refers to an RNA element that is derived from another natural source (e.g., another organism) or extracted from its natural environment (e.g., fused, attached or conjugated to another molecule) or is not normally found in nature.
[0111] In particular, as used herein, the term "heterologous RNA element of interest" refers to an RNA element that is not normally closely associated with viruses / virus-like particles (VLPs) in nature.
[0112] In a preferred embodiment, the RNA element of interest is a heterologous RNA element of interest, as described herein.
[0113] As described herein, when a viral capsid protein or a fragment or derivative thereof having capsid protein function is fused / bound to at least one RNA binding domain, and when at least one RNA binding domain binds / interacts with a recruiting RNA motif, the RNA element of interest contacts the capsid protein, and thus, a circular RNA (circRNA) molecule containing the RNA element of interest is encapsidated / encapsulated in the capsid structure of a virus-like particle.
[0114] The term "binding" according to the present invention preferably relates to specific binding. "Specific binding" means that a compound (e.g., an RNA binding domain, also known as an aptamer binding protein (ABP)) binds more strongly to a target specific for the compound (e.g., a recruiting RNA motif, also known as an aptamer) than to another target. If a compound binds to a target with a dissociation constant (K) greater than that for a second target, the compound will bind to the target more strongly than to another target. d ) lower dissociation constant with the first target, then the compound binds more strongly to the first target than to the second target. Preferably, the dissociation constant (K d ) is greater than the dissociation constant (K) of the target to which the compound does not specifically bind d ) is more than 10 times lower, preferably more than 20 times, more preferably more than 50 times, even more preferably more than 100 times, more than 200 times, more than 500 times or more than 1000 times lower.
[0115] The term "K d " (usually measured in "mol / L" and sometimes abbreviated "M") is intended to refer to the dissociation equilibrium constant for a specific interaction between a compound (e.g., a compound of the invention) and a target molecule.
[0116] Methods for determining the binding affinity of a compound (i.e., for determining the dissociation constant K dMethods) are known to those of ordinary skill in the art and can be selected, for example, from the following methods known in the art: techniques based on surface plasmon resonance (SPR), biomembrane interferometry (BLI), enzyme-linked immunosorbent assay (ELISA), flow cytometry, isothermal titration calorimetry (ITC), analytical ultracentrifugation, radioimmunoassay (RIA or IRMA) and enhanced chemiluminescence (ECL). Typically, the dissociation constant K d Determined at 20°C, 25°C, 30°C or 37°C.
[0117] As described herein, circular RNA molecules comprising an RNA element of interest and / or a recruiting RNA motif can be generated from a linear polynucleotide capable of circularization.
[0118] As used herein, the term "linear polynucleotide capable of circularization" (particularly in the context of covalent circularization) refers to a DNA or RNA polynucleotide capable of forming a circular structure in which the 5' end and the 3' end (particularly the 5' end and the 3' end of one of its exons) are covalently linked to each other.
[0119] This circular structure can be achieved by back-splicing (e.g., protein-assisted back-splicing or autocatalytic back-splicing). For back-splicing, the linear polynucleotide is required to include 5' and 3' back-splicing intron sequences. When the 5' back-splicing intron sequence is connected to the upstream 3' back-splicing intron sequence, a circular polynucleotide is generated from a linear polynucleotide, particularly from an exon of a linear polynucleotide, by back-splicing.
[0120] Therefore, in order to be able to circularize, the linear polynucleotide as described herein specifically comprises from 5' to 3' in the following order:
[0121] The first back-splicing intron sequence,
[0122] The first part of the RNA motif is recruited,
[0123] The nucleotide sequence of interest,
[0124] recruits the second part of the RNA motif, and
[0125] The second back-splicing intron sequence.
[0126] As described herein, a linear polynucleotide capable of circularization can be a DNA or RNA polynucleotide.
[0127] The back-splicing intron sequence is preferably an intron (e.g., Alu element) containing splice sites along short inverted repeats to allow protein-assisted circularization of exons. More preferably, the back-splicing intron sequence is from the human ZKSCAN1 gene. In humans, exon 2 and exon 3 of ZKSCAN1 are spliced together by protein-assisted back-splicing to form a covalently linked 668-nt circular RNA (referred to as circZKSCAN1). The ZKSCAN1 introns have been rearranged so that after transcription, the heterologous single internal exon becomes circular by a protein-assisted back-splicing reaction. Even more preferably, the first back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 34, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or the second back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 34. IDNO: 35, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0128] Alternatively, the autocatalytic back-splicing intron sequence is preferably derived from a group I or group II intron. More preferably, the autocatalytic back-splicing intron sequence is derived from the group I intron T4 from the bacteriophage T4 td gene. The intron has been split and rearranged so that after transcription, a single internal exon becomes circular by a group I splicing reaction. Even more preferably, the first autocatalytic back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 43, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or the second back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 43. The nucleotide sequence of NO:44, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0129] As used herein, the term "protein-assisted backsplicing" refers to backsplicing regulated by splicing factors. CircRNAs are generated by splicing of pre-mRNA between exons in reverse order. As a variant of linear splicing, protein-assisted backsplicing requires spliceosome assembly. Two flanking backsplicing intronic sequences are required to generate circular RNAs.
[0130] As used herein, the term "autocatalytic backsplicing" refers to backsplicing in the absence of splicing factors. Preferably, circRNAs are produced by linear RNAs comprising self-splicing group I or group II introns. Group I and group II introns are two types of RNA enzymes (ribozymes) that catalyze their own splicing by different mechanisms. The flanking self-splicing group I and group II introns included in linear RNA molecules can be obtained from or derived from any organism (e.g., bacteria, bacteriophages, and eukaryotic organisms). The group I introns of the bacteriophage T4 thymidylate synthase (td) gene are well characterized to cyclize RNA. When the td intron sequence is displaced and flanked by any exon sequence, the exon is cyclized by an autocatalytic transesterification reaction.
[0131] As used herein, the term "circular RNA (circRNA) molecule" also refers to a single-stranded RNA that, unlike cellular linear RNA, is artificially designed to self-anneal into a stable non-covalent loop even in the absence of one or more RNA-binding proteins (e.g., cap-binding protein or polyA-binding protein).
[0132] As used herein, the term "linear polynucleotide capable of cyclization" (particularly in the context of non-covalent cyclization) refers to a DNA or RNA (or mixed DNA and RNA) polynucleotide capable of forming a circular structure, wherein the 5' end and the 3' end are non-covalently linked with high stability. For example, if the RNA ends can be interwoven together into a highly stable pseudoknot, G-quadruplex or base triplet, similar to the RNA component (TR) of the telomerase ribonucleoprotein complex (composed of TERT, TR and cofactors) or the 3' end of the MALAT1 transcript, such a non-covalent structure is formed. The difference from the naturally occurring pseudoknot, G-quadruplex or base triplet is that the two ends cooperate to form such a structure (whereas in naturally occurring RNAs, a continuous internal extension, or one end folds onto itself alone, regardless of the end to which it is intended to be facing). Non-covalent structures can also be formed when the two ends are designed to fold into an aptamer or chelating shape that binds to a common (connected) entity (e.g., free nucleotides or other small molecules).
[0133] In the context of non-covalent RNA loops, the circularized structure has the function of preventing exposure of the 5' end of uncapped or decapped synthetic or natural RNA (usually having a 5'-monophosphate, 5'-diphosphate or 5'-triphosphate chemical structure), and simultaneously preventing exposure of the 3' end with or without a poly-A tail. Thus, the definition of having a stable non-covalent closed loop is that such circularized RNA is not susceptible to either 5' or 3' exonucleases while linear polynucleotides in the same preparation are digested.
[0134] In addition, in the context of non-covalent RNA rings, the cyclized structure can serve as a recruitment RNA motif (also referred to as an aptamer). However, the 5' end or 3' end itself does not bind to the RNA binding domain, but the cyclized structure can be recognized and recruited into the nucleotide / protein interaction. Then, the recruited material can be further used for encapsidation as a virus-like particle (VLP). For example, the nucleotide binding motif for recruiting the non-covalently closed circular RNA in the VLP can be obtained from the protein known to bind RNA triple helix. For example, this protein domain can be found in yeast ribosome binding protein Stm1p27 or splicing factor PSF, P54nrb or U2AF6529. For example, the nucleotide binding motif for the recruitment of the circular RNA with G quadruplex closure can be found in protein AVEN, CNBP, DDX21, DDX3X, DHX36, FMRP, nucleolin or G3BP1.
[0135] As used herein, the term "nucleotide sequence of interest" refers to a DNA or RNA sequence. The DNA sequence can encode an RNA element or protein. The RNA element or protein encoded by the DNA sequence has a specific function and is therefore of interest. In the case where the nucleotide sequence of interest is an RNA sequence, the RNA sequence itself can play a specific function as an RNA element, or can encode a protein. The function of the RNA element is, for example, inhibition of gene expression (e.g., by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (e.g., to elicit an immune response). In a primary example, the expression of the spike protein of SARS-CoV-2 is induced to elicit an immune response against the SARS-CoV-2 virus.
[0136] Preferably, the RNA element of interest is selected from the group consisting of coding RNA or non-coding RNA. More preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest. The product of interest can be a protein or polypeptide of interest. The RNA element of interest can also be a non-coding RNA (e.g., miRNA or RNA complementary to miRNA). Non-coding RNAs are generally used to silence the corresponding target gene or silence or improve the expression of a group of genes.
[0137] As described herein, in a linear polynucleotide capable of circularization, the recruiting RNA motif is split into two parts in such a way that these parts themselves no longer have a significant recruiting function: a "first part of the recruiting RNA motif" and a "second part of the recruiting motif". For example, the recruiting motif can be split as follows.
[0138]
[0139]
[0140]
[0141]
[0142]
[0143] The first portion of the recruiting RNA motif and the second portion of the recruiting RNA motif form a functional recruiting RNA motif after circularization.
[0144] The term "recruiting RNA motif" is defined as above. As used herein, the term "functional recruiting RNA motif" refers to a recruiting RNA motif that can (specifically) bind to an RNA binding domain. The term "RNA binding domain" is also defined above. The advantage of this cyclization method is that the recruiting RNA motif can only become functional after cyclization because it is complete through cyclization. Therefore, only circular RNA is packaged into virus-like particles (VLPs). As described herein, this improves the quality of the circular RNA delivery method.
[0145] As used herein, the term "vector" refers to a structure that transfers genetic material into a cell. As used herein, the term "vector" encompasses viral vectors and plasmid vectors. Plasmids with special structural features are typically used in laboratories for cloning purposes. These plasmids are typically non-conjugated, but may have more features, particularly multiple cloning sites, in which multiple restriction endonuclease cleavage sites allow for the insertion of transgenic inserts. Plasmids can be specifically used as transcription vectors, and such plasmids may lack key sequences for protein expression. Plasmids used for protein expression are referred to as expression vectors, including elements (e.g., ribosome binding sites, start codons, and stop codons) for protein translation. Viral vectors are typically genetically engineered viruses carrying modified viral DNA or RNA, which have been converted to non-infectious, but still contain viral promoters and transgenics, thus allowing for the translation of transgenics by viral promoters. However, since viral vectors often lack infection sequences, they require helper viruses or packaging lines for large-scale transfection. Baculoviruses can be used as viral vectors.
[0146] Residues in two or more polypeptides or polynucleotides are considered to "correspond" to each other if they occupy similar positions in the polypeptide or polynucleotide structure. It is well known in the art that similar positions in two or more polypeptides or polynucleotides can be determined by aligning polypeptide or polynucleotide sequences based on amino acid sequence or nucleotide sequence similarity. Such alignment tools are well known to those skilled in the art and are available, for example, on the World Wide Web, such as ClustalW (www.ebi.ac.uk / clustalw) or Align (http: / / www.ebi.ac.uk / emboss / align / index.html) using standard settings, preferably Align EMBOSS: needle, Matrix: Blosum62, Gap Open 10.0, GapExtend 0.5.
[0147] As used herein, the term "naturally occurring" as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a source in nature and has not been intentionally modified by humans in the laboratory is naturally occurring.
[0148] As used herein, the term "artificial" as applied to an object refers to the fact that the object cannot be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) can be isolated from a source in nature and intentionally modified by humans in a laboratory, which is artificial. A polypeptide or polynucleotide sequence produced by humans in a laboratory (e.g., chemically synthesized) is also artificial.
[0149] As used herein, the term "treatment", particularly "therapeutic treatment", refers to any therapy that improves the health status of a subject with a disease and / or prolongs (increases) the life span of a subject with a disease. The therapy may eliminate the disease in a subject, prevent or slow the progression of the disease in a subject, inhibit the progression of the disease in a subject, reduce the severity of symptoms in a subject with the disease, and / or reduce recurrence in a subject who currently or previously had the disease.
[0150] Preferably, the treatment is selected from the group consisting of gene therapy, cell therapy, cancer therapy and treatment of a disease, e.g., an infectious disease (e.g., an infectious disease caused by bacteria or viruses such as SARS-CoV-2).
[0151] The present invention relates to the use of virus-like particles (VLPs) as described herein as drugs. As used herein, the term "drug" refers to a substance used for treatment (i.e., treating, improving or preventing a disease or illness). In particular, the present invention relates to virus-like particles (VLPs) as described herein for treatment. Alternatively, the present invention relates to virus-like particles (VLPs) as described herein for vaccination. In this regard, it should be noted that the active component is usually not the VLP itself, but the RNA element of interest as part of a circular RNA molecule included therein.
[0152] As used herein, the term "vaccine" refers to an agent that can be used to induce protective immunity in a recipient (e.g., a human recipient or an animal recipient). To be effective, a vaccine can induce immunity in a portion of an immunized population, because some individuals may be unable to generate a robust or protective immune response, or in some cases, any immune response. This inability may be due to the genetic background of the recipient, or due to immunodeficiency disorders (acquired or congenital) or immunosuppression (e.g., due to chemotherapy or the use of immunosuppressive drugs). Vaccine efficacy can be established in animal models.
[0153] As used herein, the term "vaccination" refers to attacking a recipient (e.g., a human recipient or an animal recipient) with a vaccine to induce specific immunity. In the context of the present invention, a recipient can be attacked with a virus-like particle (VLP) that also contains an RNA element of interest. In one embodiment, the RNA element of interest is a sequence against which protective immunity is elicited.
[0154] As used herein, the expressions "for administration" and "to be administered" have the same meaning as "ready to be administered". In other words, the statement that an active compound is "for administration" must be understood as meaning that the active compound has been formulated and made into a dosage such that the active compound is in a state in which it can exert its therapeutic activity. In the context of the present invention, a virus-like particle (VLP) as described herein may be prepared for administration.
[0155] The term "therapeutically effective amount" or "therapeutic amount" is intended to refer to the amount of a drug or pharmaceutical agent that will elicit a biological or medical response in a tissue, system, animal or human being that is sought by a researcher, veterinarian, doctor or other clinician. Dosage regimens utilizing virus-like particles (VLPs) as described herein can be selected by a skilled practitioner based on a variety of factors, including the type, species, age, weight, body mass index, sex and medical condition of the subject; the severity of the condition to be treated; the efficacy of the compound selected to be administered; the route of administration; the purpose of administration; and the renal and liver function of the subject. In the context of the present invention, virus-like particles (VLPs) as described herein can be administered or prepared for administration in a therapeutically effective / therapeutic amount.
[0156] Compositions, particularly pharmaceutical compositions comprising virus-like particles (VLPs) as described herein may include one or more adjuvants, diluents and / or carriers, all of which are preferably pharmaceutically acceptable. As used herein, the term "pharmaceutically acceptable" refers to approval by a regulatory agency of a federal or state government, or listed in the U.S. Pharmacopoeia, the European Pharmacopoeia (Ph. Eur.) or other generally recognized pharmacopoeias for use in animals, and particularly in humans.
[0157] As used herein, the term "excipients" is intended to mean all substances in a pharmaceutical composition that are not active ingredients, for example, binders, lubricants, thickeners, surfactants, preservatives, emulsifiers, buffers, flavoring agents or coloring agents.
[0158] As used herein, the term "diluent" relates to a diluting agent and / or a diluting agent. Furthermore, the term "diluent" includes a solution, a suspension (eg, a liquid or a solid suspension) and / or a medium.
[0159] As used herein, the term "vehicle" refers to one or more compatible solid or liquid fillers that are suitable for application (e.g., suitable for use in humans). The term "vehicle" refers to a natural or synthetic organic or inorganic component that is combined with an active ingredient to promote the application of the active ingredient or the penetration of the active ingredient into the intended site of action. Preferably, the vehicle component is a sterile liquid (e.g., water or oil, including those derived from mineral oil, animals or plants (e.g., peanut oil, soybean oil, sesame oil, sunflower oil, etc.)). Saline solutions and aqueous dextrose and glycerol solutions can also be used as aqueous vehicle compounds. The vehicle compound that improves or promotes the penetration of the skin in topical applications is dimethyl sulfoxide (DMSO). Another preferred vehicle consists of layered double hydroxide (LDH) nanoparticles. For example, such LDH nanoparticles may have the form of [Mg3Al(OH)8](CH3CHOHCOO), which may be obtained, for example, by the reaction of Mg(lactate)2·3H2O and Al(lactate)3 at 45°C-65°C under NaOH-controlled pH and protected from CO2 and carbonic acid. The circularized RNA may be inserted into the LDH nanoparticles and may be administered as LDH nanoparticles or in combination with VLPs.
[0160] Pharmaceutically acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro edit. 1985). Examples of suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, etc. Examples of suitable diluents include ethanol, glycerol and water.
[0161] The pharmaceutical carrier, diluent and / or adjuvant can be selected according to the expected route of administration and standard pharmaceutical practice. The pharmaceutical composition of the present invention can include any suitable adhesive, lubricant, suspending agent, coating agent and / or solubilizing agent as a carrier, adjuvant or diluent, or in addition to the carrier, adjuvant and diluent, can also include any suitable adhesive, lubricant, suspending agent, coating agent and / or solubilizing agent. Examples of suitable adhesives include starch, gelatin, natural sugars (e.g., glucose, lactose, sucrose, trehalose, corn sweeteners), natural and synthetic gums (e.g., gum arabic, tragacanth or sodium alginate), carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Preservatives, stabilizers, dyes, and even flavoring agents can be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and parahydroxybenzoates. Antioxidants and suspending agents can also be used.
[0162] As used herein, the term "subject" refers to any individual who can receive a virus-like particle (VLP) as described herein. As used herein, the term "subject" refers to any individual who can benefit from the treatment of a virus-like particle (VLP) as described herein.
[0163] The subject can be a vertebrate, such as a human, dog, cat, sheep, goat, cow, horse, camel or pig. It is particularly preferred that the "subject" is a human.
[0164] The terms "subject," "individual," or "patient" are used interchangeably herein.
[0165] Embodiments of the present invention
[0166] The present invention will now be further described. In the following paragraphs, different aspects of the present invention are defined in more detail. Unless explicitly indicated to the contrary, each aspect so defined may be combined with any other aspect. In particular, unless explicitly indicated to the contrary, any feature indicated as being preferred or beneficial may be combined with any other feature indicated as being preferred or beneficial.
[0167] The inventors unexpectedly found that circular RNAs (circRNAs) can be packaged into virus-like particles (VLPs). By incorporating the recruited RNA motif into the molecule to be packaged, circRNAs (e.g., encoding circRNAs or non-coding circRNAs) can be selectively packaged into VLPs. The recruited RNA motif can only become functional through cyclization, whereby the molecule to be packaged is packaged only with its cyclized state. Unexpectedly, these RNAs can also be packaged in the envelope of DNA viruses. These VLPs can deliver (therapeutic) circRNA molecules in vivo or in vitro.
[0168] Thus, in a first aspect, the present invention relates to a (linear) polynucleotide (capable of circularization) comprising, from 5' to 3', in the following order:
[0169] The first back-splicing intron sequence,
[0170] The first part of the RNA motif is recruited,
[0171] The nucleotide sequence of interest,
[0172] recruits the second part of the RNA motif, and
[0173] The second back-splicing intron sequence,
[0174] Wherein, the first part of the recruiting RNA motif and the second part of the recruiting RNA motif form a functional recruiting RNA motif after cyclization.
[0175] The (linear) polynucleotide (capable of circularization) may be a DNA or RNA (or a mixed DNA and RNA) polynucleotide. Preferably, the (linear) polynucleotide is a DNA polynucleotide.
[0176] The (linear) polynucleotide (capable of circularization) may be a DNA or RNA (or mixed DNA and RNA) polynucleotide capable of forming a circular structure in which the 5' end and the 3' end are covalently linked to each other.
[0177] Alternatively, the (linear) polynucleotide (capable of circularization) may be a DNA or RNA (or mixed DNA and RNA) polynucleotide capable of forming a circular structure in which the 5' end and the 3' end are non-covalently bound with high stability.
[0178] Preferably, the (linear) polynucleotide (capable of circularization) is a DNA or RNA (or mixed DNA and RNA) polynucleotide capable of forming a circular structure in which the 5' end and the 3' end are covalently linked to each other.
[0179] In particular, a circular polynucleotide is generated from a linear polynucleotide, in particular from an exon of a linear polynucleotide, by backsplicing when a 5' backsplicing intron sequence is linked to an upstream 3' backsplicing intron sequence.
[0180] The 5' end and the 3' end, in particular the 5' end and the 3' end of one of its exons, can be covalently linked to each other by connecting a first back-splicing intron sequence to a second back-splicing intron sequence. Thousands of circRNAs have been shown to be expressed in eukaryotic cells. For example, a public circRNA database and corresponding back-splicing intron sequences can be explored on circBase (http: / / www.circbase.org / ).
[0181] The back-splicing intron sequence is preferably an intron containing a splicing site and a short inverted repeat sequence (e.g., an Alu element) to allow protein-assisted circularization of the exon. More preferably, the back-splicing intron sequence is from the ZKSCAN1 gene (e.g., the human ZKSCAN1 gene). The ZKSCAN1 gene belongs to the zinc finger family gene. Even more preferably, the first back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 34, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or the second back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 34. NO:35, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0182] Alternatively, the autocatalytic back-splicing intron sequence is preferably derived from a group I or group II intron. More preferably, the autocatalytic back-splicing intron sequence is derived from the group I intron T4 from the bacteriophage T4 td gene. The intron has been split and rearranged so that after transcription, a single internal exon becomes circular by a group I splicing reaction. Even more preferably, the first autocatalytic back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 43, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto; and / or the second back-splicing intron sequence has a nucleotide sequence according to SEQ ID NO: 43. The nucleotide sequence of NO:44, or a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0183] The nucleotide sequence of interest can be a DNA or RNA sequence. The DNA sequence can encode an RNA element or protein. The RNA element or protein encoded by the DNA sequence has a specific function and is therefore of interest. If the nucleotide sequence of interest is an RNA sequence, the RNA sequence itself can play a specific function as an RNA element, or can encode a protein. The function of the RNA element is, for example, the inhibition of gene expression (for example, by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (for example, to elicit an immune response). In a prominent example, the expression of the spike protein of SARS-CoV-2 is induced to elicit an immune response against the SARS-CoV-2 virus.
[0184] Preferably, the RNA element of interest is selected from the group consisting of coding RNA or non-coding RNA. More preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest. The product of interest can be a protein or polypeptide of interest. The RNA element of interest can also be a non-coding RNA (e.g., miRNA). Non-coding RNAs are generally used to silence corresponding target genes.
[0185] In a (linear) polynucleotide (capable of cyclization), the recruiting RNA motif is divided into two parts, the first part of the recruiting RNA motif and the second part of the recruiting RNA motif, in a manner such that these parts themselves no longer have a significant recruiting function. The first part of the recruiting RNA motif and the second part of the recruiting RNA motif form a functional recruiting RNA motif after cyclization. As described herein, only functional recruiting RNA motifs can (specifically) bind to the RNA binding domain connected / fused / linked to the capsid protein of the virus or its fragment or derivative with capsid protein function (preferably through a linker), and therefore can be encapsidated / encapsulated in virus-like particles (VLPs) as part of a circular RNA (circRNA) molecule.
[0186] In one embodiment, the polynucleotide includes an internal ribosome entry site (IRES) or N6-methyladenosine (m6a) for translation initiation between the first portion of the recruiting RNA motif and the nucleotide sequence of interest. This is particularly desirable in the case where the nucleotide sequence of interest encodes a protein.
[0187] In one (further or additional) embodiment, the polynucleotide comprises a promoter at the 5' end and / or a poly A tail at the 3' end. This is particularly desirable in case the nucleotide sequence of interest encodes a protein.
[0188] In a preferred embodiment, the circularization of a (linear) polynucleotide, in particular the circularization of one of the exons of a (linear) polynucleotide into a circular polynucleotide, can be achieved by protein-assisted back-splicing or autocatalytic back-splicing (see definition above).
[0189] In another preferred embodiment, the polynucleotide does not comprise an in-frame stop codon to realize rolling circle translation after cyclization. If a protease target site, ribosome shift or ribosome jump sequence is incorporated into an open reading frame, multiple proteins can be translated by rolling circle translation. The example of a ribosome jump sequence is the F2A (or 2A-sample) sequence of foot-and-mouth disease virus (FMDV). The example of a ribosome shift sequence is a leaky tandem stop codon / start codon with the sequence UGAUGA.
[0190] In a more preferred embodiment, the recruitment RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop. For example, the recruitment motif can be divided as follows.
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197] The (linear) polynucleotide (capable of circularization) has preferably a length of between 100 and 50,000 nucleotides, more preferably a length of between 100 and 5,000 nucleotides, and even more preferably a length of between 100 and 2,000 nucleotides.
[0198] In a second aspect, the present invention relates to a vector comprising a polynucleotide according to the first aspect.
[0199] In a third aspect, the present invention relates to an artificial circular RNA molecule comprising an RNA element of interest and a recruitment RNA motif.
[0200] An artificial circular RNA molecule comprising an RNA element of interest and a recruiting RNA motif can be generated from a (linear) polynucleotide according to the first aspect (which is capable of circularization).
[0201] The artificial circular RNA molecule can be a single-stranded RNA, which, unlike linear RNA, forms a covalently closed continuous ring. Alternatively, the artificial circular RNA molecule can be a single-stranded RNA, which, unlike linear RNA, forms a non-covalently closed continuous ring (see the first aspect).
[0202] The RNA element of interest has a specific function or has a specific purpose, and is therefore of interest. The function of the RNA element of interest is, for example, the inhibition of gene expression (e.g., by using antisense RNA). Alternatively, therapeutically active RNA can be used to induce gene expression (e.g., for eliciting an immune response).
[0203] The RNA element of interest can be a coding RNA element or a non-coding RNA element.
[0204] Preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0205] The recruiting RNA motif is part of the artificial circular RNA molecule together with the RNA element of interest. Specifically, the recruiting RNA motif contained in the artificial circular RNA molecule can (specifically) bind to the RNA binding domain connected / fused / linked to the capsid protein of the virus or its fragment or derivative with capsid protein function (preferably through a linker). In this way, the artificial circular RNA molecule can be encapsidated / encapsulated in the capsid protein structure of the virus-like particle.
[0206] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0207] More preferably, the recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or the nucleotide sequence transcribed thereof), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0208] A recruitment RNA motif having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed therefrom) can be referred to as a recruitment RNA motif variant. Such a recruitment RNA motif variant is still able to (specifically) bind to the RNA binding domain as described above. For example, the experimental section provides sufficient information in this regard.
[0209] Specifically, a recruiting RNA motif selected from the group consisting of an MS2 phage operator stem-loop, a telomerase Ku binding motif, a telomerase Sm7 binding motif, an SfMu phage COM stem-loop and a PP7 phage operator stem-loop is combined with an RNA element of interest selected from the group consisting of shRNA, miRNA, protein-encoding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes as part of / included in an artificial circular RNA molecule.
[0210] As described above, the recruitment RNA motif contained in the artificial circular RNA molecule is capable of (specifically) binding to the RNA binding domain connected / fused / linked to the viral capsid protein or a fragment or derivative thereof having capsid protein function (preferably via a linker).
[0211] Preferably, at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu phage COM RNA binding protein or its RNA binding portion, and PP7 coat protein or its RNA binding portion.
[0212] More preferably, at least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0213] An RNA binding domain having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16 can be referred to as an RNA binding domain variant. Such RNA binding domain variants are still able to (specifically) bind to the recruitment RNA motif as described above. For example, the experimental part provides sufficient information in this regard.
[0214] In a preferred embodiment,
[0215] (i) at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) is the MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is the MS2 bacteriophage operator stem-loop,
[0216] (ii) at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Ku binding motif,
[0217] (iii) at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif,
[0218] (iv) at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruiting RNA motif is a SfMu bacteriophage COM stem-loop, and / or
[0219] (v) at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) is a PP7 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is a PP7 bacteriophage operator stem-loop.
[0220] In a more preferred embodiment,
[0221] at least one RNA binding domain (to which the recruiting RNA motif is capable of binding) has an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or
[0222] The recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed therefrom), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0223] The artificial circular RNA molecule has a length preferably between 50 and 50,000 nucleotides, more preferably between 50 and 5,000 nucleotides, and even more preferably between 50 and 2,000 nucleotides.
[0224] In a fourth aspect, the present invention relates to a composite comprising or involving:
[0225] (i) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain (e.g., 1, 2 or 3 RNA binding domains), and
[0226] (ii) an (artificial) circular RNA molecule comprising an RNA element of interest.
[0227] In particular, the circular RNA molecule is an artificial circular RNA molecule, preferably an artificial circular RNA molecule according to the third aspect.
[0228] In one embodiment, at least one RNA binding domain is linked / fused / connected to a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein (preferably via a linker).
[0229] In a preferred embodiment, at least one RNA binding domain is connected / fused / linked to the N-terminus and / or C-terminus of the viral capsid protein or its fragment or derivative having capsid protein function (preferably via a linker).
[0230] Any linker for coupling a viral capsid protein or a fragment or derivative thereof having capsid protein function to at least one RNA binding domain can be used. In an exemplary embodiment, the linker has an amino acid sequence according to SEQ ID NO:5.
[0231] Specifically, a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having a capsid protein function and at least one RNA binding domain exists / is produced as a fusion polypeptide. In particular, a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having a capsid protein function and at least one RNA binding domain exists / is produced as a fusion polypeptide, wherein the viral capsid protein or a fragment or derivative thereof having a capsid protein function is connected to at least one RNA binding domain via a linker.
[0232] The at least one RNA binding domain may be a naturally occurring RNA binding domain or an artificial RNA binding domain.
[0233] Preferably, at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu bacteriophage COM RNA binding protein or its RNA binding portion, and PP7 coat protein or its RNA binding portion. Therefore, preferably, the polypeptide comprises a capsid protein of a virus or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, wherein the at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu bacteriophage COM RNA binding protein or its RNA binding portion, and PP7 coat protein or its RNA binding portion. The RNA binding domain may be connected to the capsid protein of a virus or a fragment or derivative thereof having the function of a capsid protein via a linker or without a linker.
[0234] As mentioned above, (artificial) circular RNA molecules include RNA elements of interest. In one embodiment, the (artificial) circular RNA molecules comprising RNA elements of interest also include a recruitment RNA motif. The recruitment RNA motif contained in the artificial circular RNA molecule is (specifically) bound to the RNA binding domain connected / fused / connected to the capsid protein of the virus or its fragment or derivative with capsid protein function. In this way, the artificial circular RNA molecule forms a complex with the capsid protein structure.
[0235] The RNA element of interest has a specific function or has a specific purpose, and is therefore of interest. The function of the RNA element of interest is, for example, the inhibition of gene expression (e.g., by using antisense RNA). Alternatively, therapeutically active RNA can be used to induce gene expression (e.g., to induce an immune response).
[0236] The RNA element of interest can be a coding RNA element or a non-coding RNA element.
[0237] Preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0238] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0239] More preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA and ribozymes, and the recruiting RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
[0240] In a preferred embodiment,
[0241] (i) at least one RNA binding domain included in the polypeptide is an MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif (to which at least one RNA binding domain binds) is an MS2 bacteriophage operator stem-loop,
[0242] (ii) at least one RNA binding domain included in the polypeptide is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif (to which at least one RNA binding domain binds) is a telomerase Ku binding motif,
[0243] (iii) at least one RNA binding domain included in the polypeptide is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif (to which at least one RNA binding domain binds) is a telomerase Sm7 binding motif,
[0244] (iv) at least one RNA binding domain included in the polypeptide is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruiting RNA motif (to which at least one RNA binding domain binds) is a SfMu bacteriophage COM stem-loop, and / or
[0245] (v) at least one RNA binding domain included in the polypeptide is a PP7 coat protein or an RNA binding portion thereof, and the recruiting RNA motif (to which at least one RNA binding domain binds) is the PP7 bacteriophage operator stem-loop.
[0246] In a more preferred embodiment,
[0247] At least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or
[0248] The recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed therefrom), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0249] The virus can be a DNA virus or an RNA virus.
[0250] In another embodiment,
[0251] a DNA virus selected from the group consisting of papovavirus, papillomavirus, polyomavirus, adenovirus and parvovirus, or
[0252] RNA viruses are retroviruses, noroviruses or orthomyxoviruses.
[0253] In a preferred embodiment,
[0254] The polyomavirus is simian virus 40 (SV40), BK virus (BKV), JC virus (JCV) or MPy virus (MPyV),
[0255] Parvovirus is adeno-associated virus (AAV),
[0256] Retroviruses are slow viruses.
[0257] Norovirus is Norwalk virus, or
[0258] Orthomyxoviruses are either influenza A or influenza B viruses.
[0259] The capsid protein may be a capsid protein of an RNA virus or a DNA virus.
[0260] In another embodiment,
[0261] The capsid protein of a DNA virus is selected from the group consisting of a capsid protein of a papovavirus, a capsid protein of a papillomavirus, a capsid protein of a polyomavirus, a capsid protein of an adenovirus and a capsid protein of a parvovirus, or
[0262] The capsid protein of RNA virus is the capsid protein of lentivirus.
[0263] In a preferred embodiment,
[0264] (i) the parvovirus capsid protein is a capsid protein of an adeno-associated virus, preferably an AAV9 capsid protein,
[0265] (ii) the polyomavirus capsid protein is SV40 capsid protein, BKV capsid protein, JCV capsid protein or MPyV capsid protein, or
[0266] (iii) The capsid protein of the lentivirus is a nucleocapsid (NC) protein, a matrix protein (MA) or a capsid protein (CA).
[0267] In an even more preferred embodiment,
[0268] (i) the AAV9 capsid protein is an AAV9 VP1 capsid protein, an AAV9 VP2 capsid protein or an AAV9 VP3 capsid protein,
[0269] (ii) the SV40 capsid protein is SV40 VP1 capsid protein, SV40 VP2 capsid protein or SV40 VP3 capsid protein,
[0270] (iii) the BKV capsid protein is BKV VP1 capsid protein, BKV VP2 capsid protein or BKV VP3 capsid protein,
[0271] (iv) the JCV capsid protein is JCV VP1 capsid protein, JCV VP2 capsid protein or JCV VP3 capsid protein, or
[0272] (v) The MPyV capsid protein is MPyV VP1 capsid protein, MPyV VP2 capsid protein or MPyV VP3 capsid protein.
[0273] In an even more preferred embodiment,
[0274] the SV40 VP1 capsid protein having the amino acid sequence according to SEQ ID NO: 1 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0275] the SV40 VP2 capsid protein having the amino acid sequence according to SEQ ID NO: 2 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0276] The SV40 VP2 capsid protein without a DNA binding domain (woDBD) has an amino acid sequence according to SEQ ID NO: 3 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0277] the SV40 VP3 capsid protein having the amino acid sequence according to SEQ ID NO: 4 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0278] The nucleocapsid (NC) protein has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0279] The matrix protein (MA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, or
[0280] The capsid protein (CA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0281] Capsid proteins having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequences according to SEQ ID NO: 1 to SEQ ID NO: 4 can be referred to as capsid protein variants. Such capsid protein variants are still able to constitute / form the capsid of the virus, or are still able to promote the formation / formation of the capsid of the virus. For example, the experimental part provides sufficient information in this regard. The same applies to SEQ ID NO: 31 variants.
[0282] In a most preferred embodiment, the polypeptide comprising a capsid protein of a virus and at least one RNA binding domain has an amino acid sequence according to SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 or SEQ ID NO: 24, or an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 33. Variants are also encompassed. The variants have a sequence identity of 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) with the above sequences.
[0283] Figure 3A specific combination of a capsid protein of a DNA virus or a fragment or derivative thereof having a capsid protein function connected / fused / linked to an RNA binding domain is shown. For example, the SV40 VP2 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the SV40 VP3 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the BKV VP2 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the BKV VP3 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the JCV VP2 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the JCV VP3 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the MPyV VP2 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the MPyV VP3 capsid protein can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, the SV40 VP2 capsid protein without a DNA binding domain (woDBD) can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, the SV40 VP3 capsid protein without a DNA binding domain (woDBD) can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, the BKV VP2 capsid protein without a DNA binding domain (woDBD) can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, the BKV VP3 capsid protein without a DNA binding domain (woDBD) can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, the JCV VP2 capsid protein without a DNA binding domain (woDBD) can be used in combination with the specified linker and any one of the RNA binding domains listed in this figure. For example, a JCV VP3 capsid protein without a DNA binding domain (woDBD) can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, an MPyV VP2 capsid protein without a DNA binding domain (woDBD) can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, an MPyV VP3 capsid protein without a DNA binding domain (woDBD) can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, an SV40 VP1 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure.For example, the BKV VP1 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the JCV VP1 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the MPyV VP1 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the AAV VP1 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the AAV VP2 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure. For example, the AAV VP3 capsid protein can be used in combination with a specified linker and any one of the RNA binding domains listed in this figure.
[0284] In a fifth aspect, the present invention relates to a virus-like particle (VLP) comprising the complex according to the fourth aspect.
[0285] The virus-like particle (VLP) may be a DNA virus-like particle (VLP) or an RNA virus-like particle (VLP).
[0286] In one embodiment,
[0287] The DNA virus-like particle is selected from the group consisting of papovavirus-like particles, papillomavirus-like particles, polyomavirus-like particles, adenovirus-like particles and parvovirus-like particles, or
[0288] The RNA virus-like particles are retrovirus-like particles, norovirus-like particles or orthomyxovirus-like particles.
[0289] In a preferred embodiment,
[0290] The polyomavirus-like particle is a simian virus 40 (SV40)-like particle, a BK virus (BKV)-like particle, a JC virus (JCV)-like particle or a MPy virus (MPyV)-like particle,
[0291] Parvovirus-like particles are adeno-associated virus (AAV)-like particles.
[0292] Retrovirus-like particles are lentivirus-like particles.
[0293] Norovirus-like particles are Norwalk virus-like particles, or
[0294] The orthomyxovirus-like particle is an influenza A virus-like particle or an influenza B virus-like particle.
[0295] In the fourth aspect of the present invention, it is mentioned that the polypeptide as a component of the complex includes a viral capsid protein or a fragment or derivative thereof having a capsid protein function and at least one RNA binding domain. As an additional component of the complex, the (artificial) circular RNA molecule preferably comprises an RNA element of interest and a recruiting RNA motif. The recruiting RNA motif interacts / binds with at least one RNA binding domain. In this way, the (artificial) circular RNA molecule (comprising an RNA element of interest) is encapsidated / encapsulated in a virus-like particle (VLP).
[0296] In a specific embodiment, the virus-like particle is an SV40 virus-like particle, which includes a polypeptide as part of a complex, wherein the polypeptide includes the SV40 VP1 capsid protein or a fragment or derivative thereof and at least one RNA binding domain.
[0297] In another specific embodiment, the virus-like particle is an SV40 virus-like particle, and the SV40 virus-like particle includes a polypeptide as part of a complex, and the polypeptide includes SV40 VP2 capsid protein or a fragment or derivative thereof and at least one RNA binding domain. The SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP2 capsid protein or a fragment or derivative thereof and at least one RNA binding domain, and preferably further includes SV40 capsid protein VP1 or SV40 capsid protein VP1 and VP3.
[0298] In another specific embodiment, the virus-like particle is an SV40 virus-like particle, and the SV40 virus-like particle includes a polypeptide as part of a complex, and the polypeptide includes SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain. The SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain, and preferably further includes SV40 capsid protein VP1 or SV40 capsid protein VP1 and VP2.
[0299] In an alternative embodiment, the virus-like particle is an AAV virus-like particle, which includes a polypeptide as part of a complex, wherein the polypeptide includes an AAV VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain.
[0300] In another optional embodiment, the virus-like particle is an AAV virus-like particle, and the AAV virus-like particle includes a polypeptide as part of a complex, and the polypeptide includes an AAV VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The AAV virus-like particle includes a polypeptide, and the polypeptide includes an AAV VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes an AAV capsid protein VP3 or an AAV capsid protein VP3 and VP1.
[0301] In another optional embodiment, the virus-like particle is an AAV virus-like particle, and the AAV virus-like particle includes a polypeptide as part of a complex, and the polypeptide includes an AAV VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The AAV virus-like particle includes a polypeptide, and the polypeptide includes an AAV VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes an AAV capsid protein VP3 or an AAV capsid protein VP3 and VP2.
[0302] In an optional embodiment, the virus-like particle is a lentivirus-like particle, and the lentivirus-like particle includes a polypeptide as part of a complex, and the polypeptide includes a nucleocapsid (NC) protein or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle includes a polypeptide, and the polypeptide includes a nucleocapsid (NC) protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes a lentivirus matrix protein (MA) and / or a capsid protein (CA).
[0303] In another optional embodiment, the virus-like particle is a lentivirus-like particle, and the lentivirus-like particle includes a polypeptide as part of a complex, and the polypeptide includes a matrix protein (MA) or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle includes a polypeptide, and the polypeptide includes a matrix protein (MA) or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes a lentivirus nucleocapsid (NC) protein and / or a capsid protein (CA).
[0304] In another optional embodiment, the virus-like particle is a lentivirus-like particle, which includes a polypeptide as part of a complex, the polypeptide including a capsid protein (CA) or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle includes a polypeptide including a capsid protein (CA) or a fragment or a derivative thereof and at least one RNA binding domain, preferably further including a lentivirus nucleocapsid (NC) protein and / or a matrix protein (MA).
[0305] In the above specific and optional embodiments,
[0306] It is further preferred that
[0307] (i) at least one RNA binding domain is an MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is an MS2 bacteriophage operator stem-loop,
[0308] (ii) at least one RNA binding domain is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Ku binding motif,
[0309] (iii) at least one RNA binding domain is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif,
[0310] (iv) at least one RNA binding domain is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruiting RNA motif is a SfMu bacteriophage COM stem-loop, or
[0311] (v) at least one RNA binding domain is a PP7 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is a PP7 bacteriophage operator stem-loop,
[0312] and / or
[0313] It is further preferred that
[0314] The RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0315] In a sixth aspect, the present invention relates to a virus-like particle (VLP) comprising an (artificial) circular RNA molecule comprising an RNA element of interest.
[0316] In particular, the circular RNA molecule is an artificial circular RNA molecule, preferably an artificial circular RNA molecule according to the third aspect.
[0317] In particular, the (artificial) circular RNA molecules included in the virus-like particles (VLPs) are encapsidated / encapsulated in the VLPs.
[0318] In particular, (encapsidation / encapsulation) (artificial) circular RNA molecules also include a recruitment RNA motif. Therefore, more specifically, (encapsidation / encapsulation) (artificial) circular RNA molecules include an RNA element of interest and a recruitment RNA motif. The RNA element of interest has a specific function or has a specific purpose, and is therefore of interest. The function of the RNA element of interest is, for example, the inhibition of gene expression (for example, by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (for example, to induce an immune response). The RNA element of interest can be a coding RNA element or a non-coding RNA element.
[0319] Preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0320] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0321] More preferably, the RNA molecule comprises an RNA element of interest and a recruiting RNA motif, wherein the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes, and the recruiting RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
[0322] More specifically, the (encapsulated / encapsulated) (artificial) circular RNA molecule binds to at least one RNA binding domain through the recruiting RNA motif contained therein, and the RNA binding domain is part of a polypeptide, and the polypeptide further includes a viral capsid protein or a fragment or derivative thereof having a capsid protein function. Even more specifically, the (encapsulated / encapsulated) (artificial) circular RNA molecule binds to at least one RNA binding domain through the recruiting RNA motif contained therein, and the RNA binding domain is connected / fused / linked to the viral capsid protein or a fragment or derivative thereof having a capsid protein function. The polypeptide comprising the viral capsid protein or a fragment or derivative thereof having a capsid protein function and at least one RNA binding domain is part of / included in the above-mentioned virus-like particle (VLP).
[0323] In a preferred embodiment,
[0324] (i) at least one RNA binding domain is an MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is an MS2 bacteriophage operator stem-loop,
[0325] (ii) at least one RNA binding domain is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Ku binding motif,
[0326] (iii) at least one RNA binding domain is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif,
[0327] (iv) at least one RNA binding domain is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruiting RNA motif is a SfMu bacteriophage COM stem-loop, and / or
[0328] (v) at least one RNA binding domain is a PP7 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is a PP7 bacteriophage operator stem-loop.
[0329] In a more preferred embodiment,
[0330] At least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, and / or
[0331] The recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed therefrom), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0332] The virus-like particle (VLP) may be a DNA virus-like particle (VLP) or an RNA virus-like particle (VLP).
[0333] In one embodiment,
[0334] The DNA virus-like particle is selected from the group consisting of papovavirus-like particles, papillomavirus-like particles, polyomavirus-like particles, adenovirus-like particles and parvovirus-like particles, or
[0335] The RNA virus-like particles are retrovirus-like particles, norovirus-like particles or orthomyxovirus-like particles.
[0336] In a preferred embodiment,
[0337] The polyomavirus-like particle is a simian virus 40 (SV40)-like particle, a BK virus (BKV)-like particle, a JC virus (JCV)-like particle or a MPy virus (MPyV)-like particle,
[0338] Parvovirus-like particles are adeno-associated virus (AAV)-like particles.
[0339] Retrovirus-like particles are lentivirus-like particles.
[0340] Norovirus-like particles are Norwalk virus-like particles, or
[0341] The orthomyxovirus-like particle is an influenza A virus-like particle or an influenza B virus-like particle.
[0342] The capsid protein may be a capsid protein of an RNA virus or a DNA virus.
[0343] In another embodiment,
[0344] The capsid protein of a DNA virus is selected from the group consisting of a capsid protein of a papovavirus, a capsid protein of a papillomavirus, a capsid protein of a polyomavirus, a capsid protein of an adenovirus and a capsid protein of a parvovirus, or
[0345] The capsid protein of RNA virus is the capsid protein of lentivirus.
[0346] In a preferred embodiment,
[0347] (i) the parvovirus capsid protein is a capsid protein of an adeno-associated virus, preferably an AAV9 capsid protein,
[0348] (ii) the polyomavirus capsid protein is SV40 capsid protein, BKV capsid protein, JCV capsid protein or MPyV capsid protein, or
[0349] (iii) The capsid protein of the lentivirus is a nucleocapsid (NC) protein, a matrix protein (MA) or a capsid protein (CA).
[0350] In an even more preferred embodiment,
[0351] (i) the AAV9 capsid protein is an AAV9 VP1 capsid protein, an AAV9 VP2 capsid protein or an AAV9 VP3 capsid protein,
[0352] (ii) the SV40 capsid protein is SV40 VP1 capsid protein, SV40 VP2 capsid protein or SV40 VP3 capsid protein,
[0353] (iii) the BKV capsid protein is BKV VP1 capsid protein, BKV VP2 capsid protein or BKV VP3 capsid protein,
[0354] (iv) the JCV capsid protein is JCV VP1 capsid protein, JCV VP2 capsid protein or JCV VP3 capsid protein, or
[0355] (v) The MPyV capsid protein is MPyV VP1 capsid protein, MPyV VP2 capsid protein or MPyV VP3 capsid protein.
[0356] In an even more preferred embodiment,
[0357] the SV40 VP1 capsid protein having the amino acid sequence according to SEQ ID NO: 1 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0358] the SV40 VP2 capsid protein having the amino acid sequence according to SEQ ID NO: 2 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0359] The SV40 VP2 capsid protein without a DNA binding domain (woDBD) has an amino acid sequence according to SEQ ID NO: 3 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0360] the SV40 VP3 capsid protein having the amino acid sequence according to SEQ ID NO: 4 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0361] The nucleocapsid (NC) protein has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0362] The matrix protein (MA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, or
[0363] The capsid protein (CA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0364] Capsid proteins having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequences according to SEQ ID NO: 1 to SEQ ID NO: 4 can be referred to as capsid protein variants. Such capsid protein variants are still able to constitute / form the capsid of the virus, or are still able to promote the formation / formation of the capsid of the virus. For example, the experimental part provides sufficient information in this regard. The same applies to SEQ ID NO: 31 variants.
[0365] In a most preferred embodiment, the polypeptide comprising a capsid protein of a virus and at least one RNA binding domain has an amino acid sequence according to SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 or SEQ ID NO: 24, or an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 33. Variants are also encompassed. The variants have a sequence identity of 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) with the above sequences.
[0366] Figure 3 A specific combination of a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein fused to an RNA binding domain is shown.
[0367] As mentioned above, the capsid protein of the virus or its fragment or derivative with capsid protein function and at least one RNA binding domain are preferably part of a polypeptide. This polypeptide is a part of / included in a virus-like particle (VLP). The (artificial) circular RNA molecule preferably comprises an RNA element of interest and a recruiting RNA motif. The recruiting RNA motif interacts / binds with the RNA binding domain. In this way, the (artificial) circular RNA molecule (comprising an RNA element of interest) is encapsidated / encapsulated in a virus-like particle (VLP).
[0368] In a specific embodiment, the virus-like particle is an SV40 virus-like particle, and the SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain.
[0369] In another specific embodiment, the virus-like particle is an SV40 virus-like particle, and the SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes SV40 capsid protein VP1 or SV40 capsid protein VP1 and VP3.
[0370] In another specific embodiment, the virus-like particle is an SV40 virus-like particle, and the SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP3 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The SV40 virus-like particle includes a polypeptide, and the polypeptide includes SV40 VP3 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes SV40 capsid protein VP1 or SV40 capsid protein VP1 and VP2.
[0371] In an alternative embodiment, the virus-like particle is an AAV virus-like particle, and the AAV virus-like particle comprises a polypeptide, and the polypeptide comprises an AAV VP3 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain.
[0372] In another optional embodiment, the virus-like particle is an AAV virus-like particle, and the AAV virus-like particle includes a polypeptide, and the polypeptide includes an AAV VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The AAV virus-like particle includes a polypeptide, and the polypeptide includes an AAV VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes an AAV capsid protein VP3 or an AAV capsid protein VP3 and VP1.
[0373] In another optional embodiment, the virus-like particle is an AAV virus-like particle, and the AAV virus-like particle comprises a polypeptide, and the polypeptide comprises an AAV VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The AAV virus-like particle comprises a polypeptide, and the polypeptide comprises an AAV VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further comprises an AAV capsid protein VP3 or an AAV capsid protein VP3 and VP2.
[0374] In an optional embodiment, the virus-like particle is a lentivirus-like particle, and the lentivirus-like particle comprises a polypeptide, and the polypeptide comprises a nucleocapsid (NC) protein or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle comprises a polypeptide, and the polypeptide comprises a nucleocapsid (NC) protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further comprises a lentivirus matrix protein (MA) and / or a capsid protein (CA).
[0375] In another optional embodiment, the virus-like particle is a lentivirus-like particle, and the lentivirus-like particle includes a polypeptide, and the polypeptide includes a matrix protein (MA) or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle includes a polypeptide, and the polypeptide includes a matrix protein (MA) or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes a lentivirus nucleocapsid (NC) protein and / or a capsid protein (CA).
[0376] In another optional embodiment, the virus-like particle is a lentivirus-like particle, and the lentivirus-like particle includes a polypeptide, and the polypeptide includes a capsid protein (CA) or a fragment or a derivative thereof and at least one RNA binding domain. The lentivirus-like particle includes a polypeptide, and the polypeptide includes a capsid protein (CA) or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further includes a lentivirus nucleocapsid (NC) protein and / or a matrix protein (MA).
[0377] In the above specific and optional embodiments,
[0378] It is further preferred that
[0379] (i) at least one RNA binding domain is an MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is an MS2 bacteriophage operator stem-loop,
[0380] (ii) at least one RNA binding domain is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Ku binding motif,
[0381] (iii) at least one RNA binding domain is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif,
[0382] (iv) at least one RNA binding domain is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruiting RNA motif is a SfMu bacteriophage COM stem-loop, or
[0383] (v) at least one RNA binding domain is a PP7 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is a PP7 bacteriophage operator stem-loop,
[0384] and / or
[0385] It is further preferred that
[0386] The RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0387] In an alternative embodiment, a virus-like particle (VLP) comprises the complex according to the fourth aspect of the invention.
[0388] In a seventh aspect, the present invention relates to an (in vitro) method for producing a virus-like particle (VLP), the virus-like particle comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in the fifth aspect or the sixth aspect, the method comprising the following steps:
[0389] (i) providing cells, and
[0390] (ii) introducing the following into a cell, thereby producing a virus-like particle (VLP), wherein the virus-like particle includes an artificial circular RNA molecule comprising an RNA element of interest:
[0391] (iia) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide, and
[0392] (iib) a (linear) polynucleotide (capable of circularization) according to the first aspect, a vector according to the second aspect, an artificial circular RNA molecule comprising an RNA element of interest, or an artificial circular RNA molecule according to the third aspect.
[0393] The introduction of the polypeptide in step (ii / iia) into the cell can be performed by microinjection, electroporation or lipofection. The polynucleotide preferably integrated in the vector (e.g., expression vector) can be introduced into the cell by transfection, transformation, microinjection, electroporation or lipofection in step (ii / iia). The polynucleotide is then transcribed or transcribed and translated into the corresponding product in the cell. Those skilled in the art are familiar with the molecular biology techniques (e.g., transfection, transformation, microinjection, electroporation or lipofection) used to introduce polypeptides or polynucleotides into cells, and know how to perform these techniques.
[0394] The introduction of the (linear) polynucleotide (capable of circularization) preferably integrated into the vector in step (ii / iib) into the cell can be carried out by transfection, transformation, microinjection, electroporation or liposome transfection. Accordingly, the artificial circular RNA molecule can be introduced into the cell in step (ii / iib).
[0395] As described above, in step (ii / iia), a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain is introduced into a cell.
[0396] In one embodiment, at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu phage COM RNA binding protein or its RNA binding portion and PP7 coat protein or its RNA binding portion.
[0397] In a more preferred embodiment, at least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0398] The capsid protein may be a capsid protein of an RNA virus or a DNA virus.
[0399] In another embodiment,
[0400] The capsid protein of a DNA virus is selected from the group consisting of a capsid protein of a papovavirus, a capsid protein of a papillomavirus, a capsid protein of a polyomavirus, a capsid protein of an adenovirus and a capsid protein of a parvovirus, or
[0401] The capsid protein of RNA virus is the capsid protein of lentivirus.
[0402] In a preferred embodiment,
[0403] (i) the parvovirus capsid protein is a capsid protein of an adeno-associated virus, preferably an AAV9 capsid protein,
[0404] (ii) the polyomavirus capsid protein is SV40 capsid protein, BKV capsid protein, JCV capsid protein or MPyV capsid protein, or
[0405] (iii) The capsid protein of the lentivirus is a nucleocapsid (NC) protein, a matrix protein (MA) or a capsid protein (CA).
[0406] In a more preferred embodiment,
[0407] (i) the AAV9 capsid protein is an AAV9 VP1 capsid protein, an AAV9 VP2 capsid protein or an AAV9 VP3 capsid protein,
[0408] (ii) the SV40 capsid protein is SV40 VP1 capsid protein, SV40 VP2 capsid protein or SV40 VP3 capsid protein,
[0409] (iii) the BKV capsid protein is BKV VP1 capsid protein, BKV VP2 capsid protein or BKV VP3 capsid protein,
[0410] (iv) the JCV capsid protein is JCV VP1 capsid protein, JCV VP2 capsid protein or JCV VP3 capsid protein, or
[0411] (v) The MPyV capsid protein is MPyV VP1 capsid protein, MPyV VP2 capsid protein or MPyV VP3 capsid protein.
[0412] In an even more preferred embodiment,
[0413] the SV40 VP1 capsid protein having the amino acid sequence according to SEQ ID NO: 1 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0414] the SV40 VP2 capsid protein having the amino acid sequence according to SEQ ID NO: 2 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0415] The SV40 VP2 capsid protein without a DNA binding domain (woDBD) has an amino acid sequence according to SEQ ID NO: 3 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0416] the SV40 VP3 capsid protein having the amino acid sequence according to SEQ ID NO: 4 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0417] The nucleocapsid (NC) protein has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0418] The matrix protein (MA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, or
[0419] The capsid protein (CA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0420] Capsid proteins having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequences according to SEQ ID NO: 1 to SEQ ID NO: 4 can be referred to as capsid protein variants. Such capsid protein variants are still able to constitute / form the capsid of the virus, or are still able to promote the formation / formation of the capsid of the virus. For example, the experimental part provides sufficient information in this regard. The same applies to SEQ ID NO: 31 variants.
[0421] In a most preferred embodiment, the polypeptide comprising a capsid protein of a virus and at least one RNA binding domain has an amino acid sequence according to SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 or SEQ ID NO: 24, or an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 33. Variants are also encompassed. The variants have a sequence identity of 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) with the above sequences.
[0422] Figure 3 A specific combination of a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein fused to an RNA binding domain is shown.
[0423] As described above, in step (ii / iib), the artificial circular RNA molecule is introduced into the cell. In particular, the artificial circular RNA molecule comprises an RNA element of interest. More particularly, the artificial circular RNA molecule also comprises a recruiting RNA motif. Therefore, even more particularly, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif.
[0424] The RNA element of interest has a specific function or has a specific purpose, and is therefore of interest. The function of the RNA element of interest is, for example, the inhibition of the expression of a gene (e.g., by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (e.g., to induce an immune response). The RNA element of interest can be a coding RNA element or a non-coding RNA element.
[0425] Preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0426] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0427] More preferably, the recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or the nucleotide sequence transcribed thereof), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0428] Even more preferably, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif, wherein the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes, and the recruiting RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
[0429] Even more preferably, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif, wherein the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-encoding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes, and the recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed thereof), and nucleotide sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0430] Specifically, the RNA binding domain and the recruiting RNA motif may be a pair selected from the above group.
[0431] For further preferred embodiments of the artificial circular RNA molecule and the RNA binding domain, please refer to the third to sixth aspects of the present invention.
[0432] For further preferred embodiments of virus-like particles (VLPs), see the fifth and sixth aspects of the present invention.
[0433] In the process of forming virus-like particles (VLPs) in cells, the recruitment RNA motif specifically contained in the artificial circular RNA molecule binds to at least one RNA binding domain, and the RNA binding domain is connected / fused / linked to the capsid protein of the virus or its fragment or derivative having the function of the capsid protein. In this way, the artificial circular RNA molecule (and the RNA element of interest further contained therein) is encapsidated / encapsulated in the capsid structure of the virus-like particle (VLP).
[0434] In one example, a virus-like particle (VLP) of an SV40 virus comprising an artificial circular RNA molecule is produced. For this purpose, a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising an SV40 VP1 capsid protein or a fragment or derivative thereof and at least one RNA binding domain is introduced into a cell. The artificial circular RNA molecule introduced into the cell can be an RNA molecule as defined above.
[0435] In another example, virus-like particles (VLPs) of AAV viruses including artificial circular RNA molecules are produced. For this purpose, a polynucleotide comprising a nucleotide sequence encoding a polypeptide is introduced into a cell, wherein the polypeptide comprises an AAV VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain. The artificial circular RNA molecule introduced into the cell can be an RNA molecule as defined above.
[0436] Additional (auxiliary) elements may further be introduced into the cells to aid / facilitate the formation of virus-like particles (VLPs).
[0437] In one example, virus-like particles (VLPs) of SV40 virus including artificial circular RNA molecules were generated.
[0438] In this process, in addition to introducing a polynucleotide comprising a nucleotide sequence encoding a polypeptide into the cell, the polypeptide comprising SV40 VP2 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0439] A polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1, or a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1 and a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP3 are also introduced into the cells.
[0440] Alternatively, in addition to introducing into the cell a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0441] A polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1, or a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1 and a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP2 are also introduced into the cells.
[0442] The above polynucleotide may be included in a vector (e.g., a viral vector or a plasmid vector). The nucleotide sequence encoding the above capsid protein may also be part of a single polynucleotide, for example, included in a single vector. For example, a single polynucleotide included in a single vector may include a nucleotide sequence encoding a polypeptide (the polypeptide includes SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain), as well as a nucleotide sequence encoding SV40 VP1 capsid protein and / or a nucleotide sequence encoding SV40 VP2 capsid protein.
[0443] In another example, virus-like particles (VLPs) of AAV viruses including artificial circular RNA molecules were generated.
[0444] In this process, in addition to introducing a polynucleotide comprising a nucleotide sequence encoding a polypeptide into the cell, the polypeptide comprising an AAV VP2 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0445] A polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP3, or a polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP3 and a polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP1 are also introduced into the cells.
[0446] Alternatively, in addition to introducing into the cell a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising an AAV VP1 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0447] A polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP3, or a polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP3 and a polynucleotide comprising a nucleotide sequence encoding AAV capsid protein VP2 are also introduced into the cells.
[0448] The above-mentioned polynucleotide can be included in a vector (e.g., a viral vector or a plasmid vector). The nucleotide sequence encoding the above-mentioned capsid protein can also be part of a single polynucleotide, for example, included in a single vector. For example, a single polynucleotide, for example, included in a single vector, can include a nucleotide sequence encoding a polypeptide (the polypeptide includes an AAV VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain), and a nucleotide sequence encoding an AAV VP2 capsid protein and / or a nucleotide sequence encoding an AAV VP1 capsid protein.
[0449] When producing virus-like particles (VLPs) of AAV viruses comprising (heterologous) RNA molecules, additional auxiliary elements (e.g., adenovirus auxiliary genes E4, E2a and VA) are preferably present. The auxiliary elements further assist / facilitate the formation of virus-like particles (VLPs).
[0450] In a further example, a virus-like particle (VLP) of a lentivirus comprising an artificial circular RNA molecule is produced. For this purpose, a polynucleotide comprising a nucleotide sequence encoding a polypeptide is introduced into a cell, wherein the polypeptide comprises a nucleocapsid (NC) protein or a fragment or derivative thereof and at least one RNA binding domain. The artificial circular RNA molecule introduced into the cell can be an RNA molecule as defined above.
[0451] Additional (auxiliary) elements may further be introduced into the cells to assist / facilitate the formation of virus-like particles (VLPs).
[0452] In one example, a lentiviral virus-like particle (VLP) comprising an artificial circular RNA molecule was generated.
[0453] In this process, in addition to introducing a polynucleotide comprising a nucleotide sequence encoding a polypeptide into the cell, the polypeptide comprises a nucleocapsid (NC) protein or a fragment or derivative thereof and at least one RNA binding domain,
[0454] A polynucleotide comprising a nucleotide sequence encoding a matrix protein (MA) and / or a polynucleotide comprising a nucleotide sequence encoding a capsid protein (CA) is also introduced into the cell.
[0455] Alternatively, in addition to introducing into the cell a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising matrix protein (MA) or a fragment or derivative thereof and at least one RNA binding domain,
[0456] A polynucleotide comprising a nucleotide sequence encoding a nucleocapsid (NC) protein and / or a polynucleotide comprising a nucleotide sequence encoding a capsid protein (CA) is also introduced into the cell.
[0457] Alternatively, in addition to introducing into the cell a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising a capsid protein (CA) or a fragment or derivative thereof and at least one RNA binding domain,
[0458] A polynucleotide comprising a nucleotide sequence encoding a nucleocapsid (NC) protein and / or a polynucleotide comprising a nucleotide sequence encoding a matrix protein (MA) is also introduced into the cell.
[0459] These additional capsid proteins assist / facilitate the formation of VLPs.
[0460] In addition, the POL gene encoding viral protease (PRO), the reverse transcriptase (RT) with non-functional integrase gene (IN) can be introduced into the cell. In addition, the VSVG (ENV) gene encoding viral surface glycoprotein (gp160) can be introduced into the cell, and the glycoprotein is finally divided into surface protein gp120 (SU) and transmembrane protein gp41 (TM).
[0461] The above-mentioned polynucleotide can be included in a vector (e.g., a viral vector or a plasmid vector). The nucleotide sequence encoding the above-mentioned capsid protein can also be part of a single polynucleotide, for example, included in a single vector. For example, a single polynucleotide, for example, included in a single vector, can include a nucleotide sequence encoding a nucleocapsid (NC) protein and at least one RNA binding domain, as well as a nucleotide sequence encoding a matrix protein (MA) and / or a nucleotide sequence encoding a capsid protein (CA).
[0462] In an eighth aspect, the present invention relates to an (in vitro) method for producing a virus-like particle (VLP), the virus-like particle comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in the fifth aspect or the sixth aspect, the method comprising the following steps:
[0463] (i) providing a virus-like particle (VLP), wherein the virus-like particle comprises a polypeptide, wherein the polypeptide comprises a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain,
[0464] (ii) disassembling the VLPs,
[0465] (iii) adding an artificial circular RNA molecule comprising an RNA element of interest or an artificial circular RNA molecule according to the third aspect,
[0466] (iv) reassembling the disassembled VLPs,
[0467] Virus-like particles (VLPs) are thereby produced, which include artificial circular RNA molecules comprising the RNA element of interest.
[0468] The virus-like particle (VLP) provided in step (i) may be a DNA virus-like particle (VLP) or an RNA virus-like particle (VLP).
[0469] In one embodiment,
[0470] The DNA virus-like particle is selected from the group consisting of papovavirus-like particles, papillomavirus-like particles, polyomavirus-like particles, adenovirus-like particles and parvovirus-like particles, or
[0471] The RNA virus-like particles are retrovirus-like particles, norovirus-like particles or orthomyxovirus-like particles.
[0472] In a preferred embodiment,
[0473] The polyomavirus-like particle is a simian virus 40 (SV40)-like particle, a BK virus (BKV)-like particle, a JC virus (JCV)-like particle or a MPy virus (MPyV)-like particle,
[0474] Parvovirus-like particles are adeno-associated virus (AAV)-like particles.
[0475] Retrovirus-like particles are lentivirus-like particles.
[0476] Norovirus-like particles are Norwalk virus-like particles, or
[0477] The orthomyxovirus-like particle is an influenza A virus-like particle or an influenza B virus-like particle.
[0478] The capsid protein may be a capsid protein of an RNA virus or a DNA virus.
[0479] In another embodiment,
[0480] The capsid protein of a DNA virus is selected from the group consisting of a capsid protein of a papovavirus, a capsid protein of a papillomavirus, a capsid protein of a polyomavirus, a capsid protein of an adenovirus and a capsid protein of a parvovirus, or
[0481] The capsid protein of RNA virus is the capsid protein of lentivirus.
[0482] In a preferred embodiment,
[0483] (i) the parvovirus capsid protein is a capsid protein of an adeno-associated virus, preferably an AAV9 capsid protein,
[0484] (ii) the polyomavirus capsid protein is SV40 capsid protein, BKV capsid protein, JCV capsid protein or MPyV capsid protein, or
[0485] (iii) The capsid protein of the lentivirus is a nucleocapsid (NC) protein, a matrix protein (MA) or a capsid protein (CA).
[0486] In an even more preferred embodiment,
[0487] (i) the AAV9 capsid protein is an AAV9 VP1 capsid protein, an AAV9 VP2 capsid protein or an AAV9 VP3 capsid protein,
[0488] (ii) the SV40 capsid protein is SV40 VP1 capsid protein, SV40 VP2 capsid protein or SV40 VP3 capsid protein,
[0489] (iii) the BKV capsid protein is BKV VP1 capsid protein, BKV VP2 capsid protein or BKV VP3 capsid protein,
[0490] (iv) the JCV capsid protein is JCV VP1 capsid protein, JCV VP2 capsid protein or JCV VP3 capsid protein, or
[0491] (v) The MPyV capsid protein is MPyV VP1 capsid protein, MPyV VP2 capsid protein or MPyV VP3 capsid protein.
[0492] In an even more preferred embodiment,
[0493] the SV40 VP1 capsid protein having the amino acid sequence according to SEQ ID NO: 1 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0494] the SV40 VP2 capsid protein having the amino acid sequence according to SEQ ID NO: 2 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0495] The SV40 VP2 capsid protein without a DNA binding domain (woDBD) has an amino acid sequence according to SEQ ID NO: 3 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0496] the SV40 VP3 capsid protein having the amino acid sequence according to SEQ ID NO: 4 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0497] The nucleocapsid (NC) protein has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto,
[0498] The matrix protein (MA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto, or
[0499] The capsid protein (CA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0500] Capsid proteins having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity with the amino acid sequences according to SEQ ID NO: 1 to SEQ ID NO: 4 can be referred to as capsid protein variants. Such capsid protein variants are still able to constitute / form the capsid of the virus, or are still able to promote the formation / formation of the capsid of the virus. For example, the experimental part provides sufficient information in this regard. The same applies to SEQ ID NO: 31 variants.
[0501] In a further embodiment, at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu phage COM RNA binding protein or its RNA binding portion and PP7 coat protein or its RNA binding portion.
[0502] In a preferred embodiment, at least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and amino acid sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0503] In a most preferred embodiment, the polypeptide comprising a capsid protein of a virus and at least one RNA binding domain has an amino acid sequence according to SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 or SEQ ID NO: 24, or an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 33. Variants are also encompassed. The variants have a sequence identity of 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) with the above sequences.
[0504] Figure 3 A specific combination of a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein fused to an RNA binding domain is shown.
[0505] In step (iii), an artificial circular RNA molecule is added. In particular, the artificial circular RNA molecule comprises an RNA element of interest. More particularly, the artificial circular RNA molecule also comprises a recruiting RNA motif. Therefore, even more particularly, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif.
[0506] The RNA element of interest has a specific function or has a specific purpose, and is therefore of interest. The function of the RNA element of interest is, for example, the inhibition of the expression of a gene (e.g., by the application of antisense RNA). Alternatively, therapeutically active RNA can be applied to induce gene expression (e.g., to induce an immune response). The RNA element of interest can be a coding RNA element or a non-coding RNA element.
[0507] Preferably, the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
[0508] Preferably, the recruiting RNA motif is selected from the group consisting of the MS2 phage operator stem-loop, the telomerase Ku binding motif, the telomerase Sm7 binding motif, the SfMu phage COM stem-loop and the PP7 phage operator stem-loop.
[0509] More preferably, the recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or the nucleotide sequence transcribed thereof), and a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0510] Even more preferably, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif, wherein the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes, and the recruiting RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
[0511] Even more preferably, the artificial circular RNA molecule comprises an RNA element of interest and a recruiting RNA motif, wherein the RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-encoding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs and ribozymes, and the recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15 (or a nucleotide sequence transcribed thereof), and nucleotide sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99% (i.e. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity thereto.
[0512] For further preferred embodiments of the virus-like particles provided in step (i), see the fifth and sixth aspects of the present invention.
[0513] For further preferred embodiments of the artificial circular RNA molecule added in step (iii), please refer to the third to seventh aspects of the present invention.
[0514] In a specific embodiment, the virus-like particle provided in step (i) is an SV40 virus-like particle, and the SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP1 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain.
[0515] In another specific embodiment, the virus-like particle provided in step (i) is an SV40 virus-like particle, and the SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP2 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further comprises an SV40 capsid protein VP1 or an SV40 capsid protein VP1 and VP3.
[0516] In another specific embodiment, the virus-like particle provided in step (i) is an SV40 virus-like particle, and the SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP3 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain. The SV40 virus-like particle comprises a polypeptide, and the polypeptide comprises an SV40 VP3 capsid protein or a fragment or a derivative thereof and at least one RNA binding domain, and preferably further comprises an SV40 capsid protein VP1 or an SV40 capsid protein VP1 and VP2.
[0517] In the above specific embodiment,
[0518] It is further preferred that
[0519] (i) at least one RNA binding domain included in the polypeptide as part of the VLP is the MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif contained in the added artificial circular RNA molecule is the MS2 bacteriophage operator stem-loop,
[0520] (ii) at least one RNA binding domain included in the polypeptide as part of the VLP is a Ku protein or an RNA binding portion thereof, and the recruitment RNA motif contained in the added artificial circular RNA molecule is a telomerase Ku binding motif,
[0521] (iii) at least one RNA binding domain included in the polypeptide as part of the VLP is a Sm7 protein or an RNA binding portion thereof, and the recruitment RNA motif contained in the added artificial circular RNA molecule is a telomerase Sm7 binding motif,
[0522] (iv) at least one RNA binding domain included in the polypeptide as part of the VLP is the SfMu phage COM RNA binding protein or an RNA binding portion thereof, and the recruitment RNA motif contained in the added artificial circular RNA molecule is the SfMu phage COM stem-loop, or
[0523] (v) at least one RNA binding domain included in the polypeptide as part of the VLP is a PP7 coat protein or an RNA binding portion thereof, and the recruitment RNA motif contained in the added artificial circular RNA molecule is a PP7 bacteriophage operator stem-loop,
[0524] and / or
[0525] It is further preferred that
[0526] The RNA element of interest contained in the added artificial circular RNA molecule is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA and ribozyme.
[0527] In a preferred embodiment, a virus-like particle (VLP) comprising a polypeptide comprising a capsid protein of a virus or a fragment thereof having a capsid protein function or a derivative thereof and at least one RNA binding domain provided in (i) is produced by:
[0528] (a) providing cells, and
[0529] (b) introducing a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide into a cell.
[0530] The introduction of the polypeptide in step (b) into the cell can be performed by microinjection, electroporation or lipofection. The polynucleotide preferably integrated in a vector (e.g., an expression vector) can be introduced into the cell in step (b) by transfection, transformation, microinjection, electroporation or lipofection. The polynucleotide is then transcribed or transcribed and translated into the corresponding product in the cell. Those skilled in the art are familiar with the molecular biology techniques (e.g., transfection, transformation, microinjection, electroporation or lipofection) used to introduce polypeptides or polynucleotides into cells, and know how to perform these techniques.
[0531] In one example, virus-like particles (VLPs) of SV40 viruses including artificial circular RNA molecules were produced. For this purpose, a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising SV40 VP1 capsid protein or a fragment or derivative thereof and at least one RNA binding domain was introduced into a cell.
[0532] Additional elements that aid / promote VLP formation may further be introduced into the cells.
[0533] In one example, virus-like particles (VLPs) of SV40 virus were produced.
[0534] In this process, in addition to introducing a polynucleotide comprising a nucleotide sequence encoding a polypeptide into the cell, the polypeptide comprising SV40 VP2 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0535] A polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1, or a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1 and a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP3 are also introduced into the cells.
[0536] Alternatively, in addition to introducing into the cell a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain,
[0537] A polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1, or a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP1 and a polynucleotide comprising a nucleotide sequence encoding SV40 capsid protein VP2 are also introduced into the cells.
[0538] The above polynucleotide may be included in a vector (e.g., a viral vector or a plasmid vector). The nucleotide sequence encoding the above capsid protein may also be part of a single polynucleotide, for example, included in a single vector. For example, a single polynucleotide included in a single vector may include a nucleotide sequence encoding a polypeptide (the polypeptide includes SV40 VP3 capsid protein or a fragment or derivative thereof and at least one RNA binding domain), as well as a nucleotide sequence encoding SV40 VP1 capsid protein and / or a nucleotide sequence encoding SV40 VP2 capsid protein.
[0539] In another preferred embodiment, the disassembly in step (ii) is achieved by chemical means. In a more preferred embodiment, the chemical means is selected from the group consisting of treatment with a reducing agent (preferably dithiothreitol (DTT), N-acetylcysteine (NALC), β-mercaptoethanol, tris (2-carboxyethyl) phosphine hydrochloride (TCEP) or thioredoxin).
[0540] In one example, a virus-like particle (VLP) of SV40 virus is produced, the virus-like particle (VLP) of SV40 virus includes a polypeptide and an artificial circular RNA molecule, the polypeptide includes a capsid protein of SV40 virus or a fragment or derivative thereof with a capsid protein function and at least one RNA binding domain, and the artificial circular RNA molecule includes an RNA element of interest and a recruiting RNA motif. Therefore, the virus-like particle (VLP) of SV40 virus including a polypeptide is assembled with dithiothreitol (DTT) at a temperature between 35°C and 40°C (e.g., at 37°C) for a period of time between 15 minutes and 30 minutes (e.g., 20 minutes), the polypeptide includes a capsid protein of SV40 virus or a fragment or derivative thereof with a capsid protein function and at least one RNA binding domain. Specifically, a solution of dithiothreitol (DTT) included between 10mM and 20mM (e.g., 15mM) can be used. Then, the solution including the artificial circular RNA molecule comprising the RNA element of interest and the RNA motif of recruitment is added to the virus-like particle (VLP) of the SV40 virus, the virus-like particle (VLP) of the SV40 virus ... Specifically, the following loading buffer can be used: 20mM Hepes-KOH buffer of 10mM ATP, pH 7.9, 80mM KCl, 40mM NH4Cl, 10mMMgCl2, 16% glycerol, 0.08% NP-40. Subsequently, reassembly is induced by adding a specific salt solution [and incubating at a temperature between 2°C and 10°C (e.g., at 4°C) for 8 hours to 12 hours (e.g., overnight)]. Generally, any buffer that allows deassembly can be used. Specifically, the following reassembly buffer can be used: 150mM sodium acetate buffer pH 5.2, 3mM CaCl2, 120mM KCl and 40mM NH4Cl.
[0541] Due to reassembly, at least one RNA binding domain binds to the recruitment RNA motif of the artificial circular RNA molecule. In this way, the artificial circular RNA molecule (and the RNA element of interest contained therein) is encapsidated / encapsulated in the capsid structure of the virus-like particle of SV40.
[0542] Preferably, the cells mentioned in the seventh and eighth aspects of the present invention are eukaryotic cells. More preferably, the eukaryotic cells are vertebrate cells, arthropod cells, yeast cells or fungal cells. Even more preferably, the vertebrate cells are mammalian cells or the arthropod cells are insect cells.
[0543] In a ninth aspect, the present invention relates to a virus-like particle (VLP) obtainable by the method according to the seventh aspect or the eighth aspect. The obtained virus-like particle is preferably a virus-like particle according to the fifth aspect or the sixth aspect of the present invention.
[0544] In a tenth aspect, the present invention relates to a composition comprising the virus-like particle according to the fifth aspect, the sixth aspect or the ninth aspect.
[0545] Preferably, the composition is a pharmaceutical composition.
[0546] The pharmaceutical composition can be administered systemically (e.g., parenterally). For example, the pharmaceutical composition can be in a form suitable for oral administration, nasal administration, or inhalation administration. The pharmaceutical composition can also be administered intravascularly, intravenously, intramuscularly, intrathecally, subcutaneously, or intraperitoneally.
[0547] The pharmaceutical composition can be administered in a single dose or multiple doses. Preferably, the pharmaceutical composition is administered in a therapeutically effective amount.
[0548] More preferably, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients, diluents and / or carriers.
[0549] In this regard, it should be noted that the active ingredient of the pharmaceutical composition is usually not the VLP itself, but the RNA element of interest comprised therein / as a part thereof.
[0550] In an eleventh aspect, the present invention relates to a virus-like particle (VLP) according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in medicine.
[0551] In this regard, it should be noted that the active component is usually not the VLP itself, but the RNA element of interest included therein / as a part thereof.
[0552] As mentioned above, the problem with RNA-based therapeutics to date has been delivering the bioactive RNA molecules with sufficiently high efficiency into the correct cells and, therefore, into the appropriate organs. Since RNases are highly efficient at degrading RNA molecules in a relatively short period of time, it is difficult to achieve long-term sustained effects and RNA-based therapeutics would require repeated applications. A delivery mechanism that prevents degradation of bioactive RNA molecules would be highly desirable.
[0553] The present inventor has encapsidated / encapsulated RNA element of interest in virus-like particles (VLP) as described herein, particularly in the capsid protein structure of virus-like particles (VLP) as described herein. In this way, RNA element of interest is safely packaged and can be effectively delivered to target cells (for example, by viral pathway). In cells / experimenters, RNA element can perform its expected function subsequently. Due to the use of the artificial circular RNA molecule comprising RNA element of interest, RNA element of interest is specifically protected from exonuclease-mediated degradation.
[0554] The RNA element of interest can be a coding RNA element or a non-coding RNA element. The RNA element of interest is preferably selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest in the form of protein-coding RNA. The product of interest can be a protein of interest. The RNA of interest can also be a non-coding RNA (e.g., miRNA). Non-coding RNAs are generally used to silence corresponding target genes.
[0555] In a twelfth aspect, the invention relates to a virus-like particle according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in therapy.
[0556] In this regard, it should be noted that the active component is usually not the VLP itself, but the RNA element of interest included therein / as a part thereof.
[0557] The present inventor has encapsidated / encapsulated RNA element of interest in virus-like particles (VLP) as described herein, particularly in the capsid protein structure of virus-like particles (VLP) as described herein. In this way, RNA element of interest is safely packaged and can be effectively delivered to target cells (for example, by viral pathway). In cells / experimenters, RNA element can perform its expected function subsequently. Due to the use of the artificial circular RNA molecule comprising RNA element of interest, RNA element of interest is specifically protected from exonuclease-mediated degradation.
[0558] The RNA element of interest can be a coding RNA element or a non-coding RNA element. The RNA element of interest is preferably selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest in the form of protein-coding RNA. The product of interest can be a protein of interest. The RNA of interest can also be a non-coding RNA (e.g., miRNA). Non-coding RNAs are generally used to silence corresponding target genes.
[0559] Preferably, the treatment is selected from the group consisting of gene therapy, cell therapy, cancer therapy and treatment of a disease, e.g., an infectious disease (e.g., an infectious disease caused by bacteria or viruses such as SARS-CoV-2).
[0560] More preferably, cancer treatment includes one or more of the following: (i) tumor growth inhibition and / or tumor cell death, (ii) reduction of tumor markers, (iii) reduction of tumor lesions and metastases, (iv) reduction of tumor burden confirmed by imaging studies (e.g., CT, MRI, PET, etc.), and (v) reduction of tumor burden confirmed by clinical assessment or self-report of the subject. Cancers particularly include lung cancer, colorectal cancer, head and neck cancer, gastric cancer, urothelial cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma (skin cancer), pancreatic cancer, brain cancer, prostate cancer, thyroid cancer, kidney cancer, adrenal cancer, liver cancer, lymphoma (lymphocyte cancer) or leukemia (blood cancer).
[0561] The twelfth aspect of the invention may alternatively be worded as follows:
[0562] A method for treating a subject, the method comprising the steps of administering the virus-like particle according to the fifth aspect, the sixth aspect or the ninth aspect or the composition according to the tenth aspect to a subject (in need thereof), thereby treating the subject.
[0563] Preferably, the treatment is selected from the group consisting of gene therapy, cell therapy, cancer therapy and treatment of a disease, e.g., an infectious disease (e.g., an infectious disease caused by bacteria or viruses such as SARS-CoV-2).
[0564] In a thirteenth aspect, the present invention relates to a virus-like particle according to the fifth, sixth or ninth aspect or a composition according to the tenth aspect for use in vaccination.
[0565] In this regard, it should be noted that the active component is usually not the VLP itself, but the RNA element of interest included therein / as a part thereof.
[0566] The present inventor has encapsidated / encapsulated RNA element of interest in virus-like particles (VLP) as described herein, particularly in the capsid protein structure of virus-like particles (VLP) as described herein. In this way, RNA element of interest is safely packaged and can be effectively delivered to target cells (for example, by viral pathway). In cells / experimenters, RNA element can perform its expected function subsequently. Due to the use of the artificial circular RNA molecule comprising RNA element of interest, RNA element of interest is specifically protected from exonuclease-mediated degradation.
[0567] The RNA element of interest can be a coding RNA element or a non-coding RNA element. The RNA element of interest is preferably selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNAs, and ribozymes. Therefore, the RNA element of interest can encode a product of interest in the form of protein-coding RNA. The product of interest can be a protein of interest. The RNA of interest can also be a non-coding RNA (e.g., miRNA). Non-coding RNAs are generally used to silence corresponding target genes.
[0568] The thirteenth aspect of the invention may alternatively be phrased as follows:
[0569] A method for vaccinating a subject, the method comprising the following steps: administering the virus-like particle according to the fifth aspect, the sixth aspect or the ninth aspect or the composition according to the tenth aspect to a subject (in need thereof), thereby vaccinating the subject.
[0570] In one example, an RNA element encoding a spike protein or a portion thereof of SARS-CoV-2 encapsidated / encapsulated in a virus-like particle (VLP) as described herein is administered to a subject for vaccination against the SARS-CoV-2 virus. Expression of a spike protein or a portion thereof of SARS-CoV-2 is induced in cells / subjects to elicit an immune response against the SARS-CoV-2 virus.
[0571] In a further aspect, the present invention relates to the use of virus-like particles (VLPs) according to the fifth, sixth or tenth aspects of the present invention for delivery of artificial circular RNA molecules (e.g., delivered to cells / subjects). The artificial circular RNA molecules particularly include RNA elements and recruitment RNA motifs.
[0572] Optionally stated, in a further aspect, the present invention relates to a method for delivering an artificial circular RNA molecule, wherein the method comprises the following steps:
[0573] introducing a virus-like particle (VLP) according to the fifth aspect, the sixth aspect or the tenth aspect of the present invention into a cell / subject, or
[0574] The virus-like particle (VLP) according to the fifth, sixth or tenth aspect of the present invention is administered to a subject in need thereof.
[0575] The artificial circular RNA molecule comprises in particular an RNA element and a recruitment RNA motif.
[0576] It has been shown that the fusion of the RNA recruitment motif to SV40 VP3 is preferred. Therefore, this combination is preferred in all aspects of the invention as described herein.
[0577] If in the context of the present invention a polynucleotide is defined by its DNA nucleotide sequence, a polynucleotide defined by its RNA nucleotide sequence is also included, and vice versa.
[0578] Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope of the present invention. Although the present invention has been described in conjunction with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, the present invention is intended to cover various modifications of the described manner for carrying out the present invention that would be apparent to those skilled in the relevant art. BRIEF DESCRIPTION OF THE DRAWINGS
[0579] The following drawings are merely illustrative of the present invention and are not to be construed in any way to limit the scope of the present invention as indicated by the appended claims.
[0580] Figure 1 : Schematic diagram of an exemplary VLP packaged with circRNA. On the left, lentivirus is used as an example: the circRNA is fused to an aptamer, which is connected to a portion of one or both of the NCMA) through an aptamer binding protein (ABP) fused to the nucleocapsid (NC) and / or matrix protein (MA). The packaging plasmid does not encode a functional integrase protein. On the right, SV40 is used as an example: for recruitment, the circRNA is fused to an aptamer, which is connected to a portion of the internal capsid protein VP3 through an aptamer binding protein (ABP) fused to VP3. VP3 binds to the inner surface of the major capsid protein VP1.
[0581] Figure 2: Synthesized constructs. Shown are the capsid expression constructs used in this work and the fusion of the capsid protein with the aptamer binding protein, and the box encoding the circRNA molecule to be packaged. For the production of lentiviral VLPs, a third-generation lentiviral system was used. Packaging and envelope plasmids were used to encode the components of the viral capsid and envelope, thereby using a modified envelope containing an aptamer binding protein (ABP) fused to NC and / or MA. A third plasmid encoding circRNA was used. For this plasmid, intron sequences from the human ZKSCAN1 gene were used to produce circRNA. They produced circRNAs consisting of: strong IRES-short reporter gene (e.g., GFP)-termination and aptamers. The highlight of circularization is that the aptamer can only become functional through circularization because it is done through circularization. In this way, only circRNA is packaged.
[0582] Figure 3 : A preferred combination of capsid protein or its fragment or derivative fused with an RNA binding domain.
[0583] Figure 4 : Schematic diagram of the method for loading SV40 particles with RNA in vitro.
[0584] Figure 5 : Real-time PCR strategy to analyze and distinguish linear RNA from circular RNA. (A) PCR design that allows to distinguish linear RNA from circular RNA. (B) PCR product of circGFPr+circGFPf using splitCOM-GFP as template. The aptamer is functional after circularization.
[0585] Figure 6 : ddPCR-based detection of linear RNA and circular RNA in SV40-derived VLPs. SV40-derived particles were produced in the presence of (A) "CircRNA COM" or (B) "CircRNA splitCOM" as described in Example 6. The absolute levels of linear RNAs and circular RNAs were quantified by ddPCR using EvaGreen Digital PCR Supermix.
[0586] Example
[0587] The following examples are given for illustrative purposes only and are not intended to limit the above invention in any way.
[0588] Example 1
[0589] Design and synthesis of synthetic nucleic acid molecules
[0590] The amino acid sequences of LVGAG (SEQ ID NO: 31), LV VSVG (SEQ ID NO: 28), SV40VP1 (SEQ ID NO: 1), SV40VP2 (SEQ ID NO: 2), SV40 VP2 woDBD (SEQ ID NO: 3), SV40 VP3 (SEQ ID NO: 4), SfMu Com binding protein (SEQ ID NO: 14) and peptide linker (GGGSGGGSGGGS; SEQ ID NO: 5) were reverse translated and the nucleotide sequences were optimized by knockout of cryptic splice sites and RNA destabilizing sequence elements, optimized for increased RNA stability, and adapted to the requirements of HEK293 cells (Homo sapiens) regarding codon usage. The nucleotide sequences were synthesized by GeneArt Gene Synthesis (Life technologies).
[0591] Two nucleotide constructs encoding circRNA and including the SfMu Com stem loop (SEQ ID NO: 13) were designed and synthesized by GeneArt Gene Synthesis (Life technologies), and the circRNA encodes GFP-HiBit (SEQ ID NO: 37+39) by protein-assisted back splicing achieved by the ZKSCAN1 intron (SEQ ID NO: 34+35). In one of the constructs (SEQ ID NO: 38), the SfMu Com stem loop (SEQ ID NO: 13) was split, and in a way that the com stem loop was functional only after the cyclization of the RNA. In the other construct (SEQ ID NO: 36), the function of the SfMuCom stem loop (SEQ ID NO: 13) was independent of the cyclization of the RNA.
[0592] Example 2
[0593] Construction of expression plasmid
[0594] The synthetic constructs were used to generate Figure 2 a. Figure 2 b and Figure 2c. The nucleotide sequences of the resulting constructs are listed here as SEQ ID NO: 17 (SV40 VP2-COM), SEQ ID NO: 19 (SV40VP2 woDBD-COM), SEQ ID NO: 23 (SV40 COM-VP1), SEQ ID NO: 21 (SV40 VP3-COM), SEQ ID NO: 25 (SV40 VP1), SEQ ID NO: 32 (LVGAG-COM), SEQ ID NO: 27 (LV VSVG), SEQ ID NO: 29 (LVPOL), SEQ ID NO: 38 (circRNA encoding GFP including splitCom) and SEQ ID NO: 36 (circRNA encoding GFP including Com). The sequences encode SV40 VP2-COM (SEQ ID NO: 18), SV40 VP2 woDBD-COM (SEQ ID NO: 20), SV40 COM-VP1 (SEQ ID NO: 24), SV40 VP3-COM (SEQ ID NO: 22), SV40 VP1 (SEQ ID NO: 26), LVGAG-COM (SEQ ID NO: 33), LV VSVG (SEQ ID NO: 28), LV POL (SEQ ID NO: 30), circRNA encoding GFP including splitCom, and circRNA encoding GFP including Com. The constructs were ligated into an expression vector that allows transient transcription of the corresponding mRNA under the control of the CMV promoter, terminating in a polyadenylation signal. The well-known signal of the SV40 virus was used here. General procedures for constructing expression plasmids are described in Sambrook, J., EF Fritsch and T. Maniatis: Cloning I / II / III, A Laboratory Manual New York / Cold Spring Harbor Laboratory Press, 1989, 2nd edition.
[0595] Example 3
[0596] Generation of circRNA-loaded lentiviral-derived particles by transient transfection of HEK 293 cells
[0597] Effectene transfection reagent (Qiagen) was used according to the manufacturer's recommendations. Figure 2The constructs shown in a were transfected into HEK 293 cells. In more detail, the following constructs were transfected in two different experiments at the indicated ratios: Experiment #1: 'LV-g / p COM' (SEQ ID NO: 29 and SEQ ID NO: 32), 'VSVG' (SEQ ID NO: 27), 'CircRNACOM' (SEQ ID NO: 36) (1:1:1). Experiment #2: 'LV-g / p COM' (SEQ ID NO: 29 and SEQ ID NO: 32), 'VSVG' (SEQ ID NO: 27), 'CircRNA splitCOM' (SEQ ID NO: 38) (1:1:1). Lentivirus-derived particles were harvested by removing the supernatant 48 hours after transfection, followed by centrifugation (1,000×g, 10 minutes at room temperature) and filtering through a filter with a pore size of 0.45 μm. The lentiviral particles are then incubated with target cells (eg, HEK293 cells) for 24 hours using standard cell culture conditions, and GFP expression is monitored by flow cytometry or fluorescence microscopy.
[0598] Example 4
[0599] Insect cell-based in vitro production of SV40-derived particles loaded with circular RNA by encapsidation
[0600] based on Figure 2 The construct shown in b was PCR-PCR-enhanced using Bac-to-Bac according to the manufacturer's recommendations. TM Baculovirus expression system (Gibco) and ExpiSf TM Baculovirus was generated using the BACI expression system (Gibco) kit. Briefly, the different constructs were cloned into the pFastBac donor plasmid, which was then transformed into the E. coli host strain DH10Bac TM This strain contains a bacmid and a helper plasmid and allows the expression of pFastBac TM The recombinant bacmid was generated after translocation of the expression construct. The resulting bacmid was then isolated and purified using ExpiFectamine TM Sf transfection reagent was used to transfect Sf9 cells (derived from the fall armyworm Spodoptera frugiperda) to quickly and efficiently transfect insect cells to produce recombinant baculoviruses. These recombinant baculoviruses were subsequently titered according to the manufacturer's recommendations and stored at -80°C until further use. To induce expression of the selected transgene in insect cells, the coding Figure 2b Recombinant baculoviruses of the constructs shown in Figure 5 were used to transduce native Sf9 cells in different combinations. Therefore, the infection was performed using the specified amount of baculovirus, expressed as the multiplicity of infection (MOI). The following experiments were performed: Experiment #1: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2 COM' (SEQ ID NO: 17) at MOI 5. Experiment #2: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2 woDBD COM' (SEQ ID NO: 19) at MOI 5. Experiment #3: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP3 COM' (SEQ ID NO: 21) at MOI 5. Experiment #4: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40COMVP1' (SEQ ID NO: 23) at MOI 5. Baculovirus-infected Sf9 cells were lysed 48 hours after transfection by 3 freeze / thaw steps, and SV40-derived particles were harvested. Subsequently, cell debris was removed by centrifugation (3,200×g, 10 minutes at room temperature), and then 20% and 40% OptiPrep TM SV40 particles were purified by ultracentrifugation using a OptiPrep gradient (Abbott). OptiPrep TM The slight diffusion zone at the interface between the concentrations was removed and the resulting pellets were stored at -80 °C or directly used for in vitro encapsidation of circular RNAs with com sequences. Therefore, COM-containing circRNA constructs were used as templates for in vitro transcription using the Hi-T7 RNA polymerase kit according to the manufacturer's recommendations, and the initial linear RNA was subsequently circularized in vitro by adding T4 RNA ligase 2. Figure 4The "disassembly and loading process" shown was initiated by treating the SVV particles obtained in Experiment #1, Experiment #2, Experiment #3 and Experiment #4 with DTT (15mM) for 20 minutes at 37°C, which caused the disassembly of SV40 VLPs. The circular 'CircRNA COM' encoding GFP diluted in loading buffer (10mM ATP, 20mM Hepes-KOH buffer pH 7.9, 80mM KCl, 40mM NH4Cl, 10mM MgCl2, 16% glycerol, 0.08% NP-40) was then added to the disassembled SV40 proteins and incubated for another 60 minutes at 37°C. Reassembly was performed by adding reassembly buffer (150mM sodium acetate buffer pH 5.2, 3mM CaCl2, 120mM KCl and 40mM NH4Cl) followed by incubation overnight at 4°C. The mixture was then treated with Salt Active Nuclease (SAN, ArcticZymes) and kept at room temperature for 10 minutes. To stop the reaction, chloroform was added and the assembled particles were recovered in the aqueous layer after centrifugation. The resulting particles were stored at -80 °C or used directly for transduction of target cells. Therefore, isolated SV40-derived particles were incubated with target cells (e.g., HEK 293 cells) for 24 hours using standard cell culture conditions and GFP expression was monitored by flow cytometry or fluorescence microscopy.
[0601] Example 5
[0602] Production of SV40-derived particles loaded with circular RNA using a baculovirus / insect cell-based expression system
[0603] based on Figure 2 b and Figure 2 The construct shown in c was PCR-PCR-enhanced using Bac-to-Bac according to the manufacturer's recommendations. TM Baculovirus expression system (Gibco) and ExpiSf TM Baculovirus was generated using the BACI expression system (Gibco) kit. Briefly, the different constructs were cloned into the pFastBac donor plasmid, which was then transformed into the E. coli host strain DH10Bac TM This strain contains a bacmid and a helper plasmid and allows the expression of pFastBac TM The recombinant bacmid was generated after translocation of the expression construct. The resulting bacmid was then isolated and purified using ExpiFectamine TMSf transfection reagent was used to transfect Sf9 cells (derived from the fall armyworm Spodoptera frugiperda) to quickly and efficiently transfect insect cells to produce recombinant baculoviruses. These recombinant baculoviruses were subsequently titered according to the manufacturer's recommendations and stored at -80°C until further use. To induce expression of the selected transgene in insect cells, the coding Figure 2 a and Figure 2Recombinant baculoviruses of the constructs shown in c were used to transduce native Sf9 cells in different combinations. Therefore, the specified amount of baculovirus (expressed as multiplicity of infection (MOI)) was used for infection. The following experiments were performed: Experiment #1: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2COM' (SEQ ID NO: 17) at MOI 5 plus infection with baculovirus encoding 'CircRNA COM' (SEQ ID NO: 36) at MOI 5. Experiment #2: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2 woDBD COM' (SEQ ID NO: 19) at MOI 5 and baculovirus encoding 'CircRNACOM' (SEQ ID NO: 36) at MOI 5. Experiment #3: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP3 COM' (SEQ ID NO: 21) at MOI 5 and encoding 'CircRNA COM' (SEQ ID NO: 36) at MOI 5. Experiment #4: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 COM VP1' (SEQ ID NO: 235) at MOI 5 and encoding 'CircRNA COM' (SEQ ID NO: 36) at MOI 5. Experiment #5: Infection with baculovirus encoding 'SV40 VP1' at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2COM' (SEQ ID NO: 17) at MOI 5 and encoding 'CircRNA splitCOM' (SEQ ID NO: 38) at MOI 5. Experiment #6: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP2 woDBD COM' (SEQ ID NO: 19) at MOI 5 and encoding 'CircRNA splitCOM' (SEQ ID NO: 38) at MOI 5.Experiment #7: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 VP3 COM' (SEQ ID NO: 21) at MOI 5 and 'CircRNA splitCOM' (SEQ ID NO: 38) at MOI 5. Experiment #8: Infection with baculovirus encoding 'SV40 VP1' (SEQ ID NO: 25) at MOI 5, combined with infection with baculovirus encoding 'SV40 COM VP1' (SEQ ID NO: 23) at MOI 5 and 'CircRNA splitCOM' (SEQ ID NO: 38) at MOI 5. Baculovirus-infected Sf9 cells were lysed 48 hours after transfection by 3 freeze / thaw steps, and SV40-derived particles were harvested. Subsequently, cell debris was removed by centrifugation (3,200 xg, 10 min at room temperature), and then 20% and 40% OptiPrep were used. TM SV40 particles were purified by ultracentrifugation using a OptiPrep gradient (Abbott). OptiPrep TM The slight diffusion zone at the interface between the concentrations is eliminated and the resulting particles are stored at -80°C or used directly for transduction of target cells. Therefore, isolated SV40-derived particles are incubated with target cells (e.g., HEK 293 cells) for 24 hours using standard cell culture conditions and GFP expression is monitored by flow cytometry or fluorescence microscopy.
[0604] Example 6
[0605] Production of SV40-derived particles loaded with circular RNA by using a HEK 293 cell-based expression system
[0606] Effectene transfection reagent (Qiagen) was used according to the manufacturer's recommendations. Figure 2 b and Figure 2c) were transfected into HEK 293 cells with the construct shown in Figure 3 (driven by the CMV promoter). Thus, transfection mixtures of different compositions were used to generate SV40-derived particles containing therapeutically active RNA. In more detail, in the following experiments, specific constructs were transfected in the indicated ratios: Experiment #1: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP2 COM' (SEQ ID NO: 17), 'CircRNA COM' (SEQ ID NO: 36) (1:1:1). Experiment #2: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP2 woDBDCOM' (SEQ ID NO: 19), 'CircRNA COM' (SEQ ID NO: 36) (1:1:1). Experiment #3: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP3 COM' (SEQ ID NO: 21), 'CircRNA COM' (SEQ ID NO: 36) (1:1:1). Experiment #4: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 COM VP1' (SEQ ID NO: 23), 'CircRNA COM' (SEQ ID NO: 36) (1: 1: 1). Experiment #5: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP2 COM' (SEQ ID NO: 17), 'CircRNA splitCOM' (SEQ ID NO: 38) (1: 1: 1). Experiment #6: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP2 woDBD COM' (SEQ ID NO: 19), 'CircRNA splitCOM' (SEQ ID NO: 38) (1: 1: 1). Experiment #7: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 VP3 COM' (SEQ ID NO: 21), 'CircRNA splitCOM' (SEQ ID NO: 38) (1: 1: 1). Experiment #8: 'SV40 VP1' (SEQ ID NO: 25), 'SV40 COM VP1' (SEQ ID NO: 23), 'CircRNA splitCOM' (SEQ ID NO: 38) (1:1:1). Transfected HEK 293 cells were lysed 48 hours after transfection by 3 freeze / thaw steps and SV40-derived particles were harvested. Subsequently, cell debris was removed by centrifugation (3,200 × g, room temperature for 10 minutes) and then 20% and 40% OptiPrep TMSV40 particles were purified by ultracentrifugation using a OptiPrep gradient (Abbott). OptiPrep TM The slight diffusion zone at the interface between the concentrations is eliminated and the resulting particles are stored at -80°C or used directly for transduction of target cells. Therefore, isolated SV40-derived particles are incubated with target cells (e.g., HEK 293 cells) for 24 hours using standard cell culture conditions and GFP expression is monitored by flow cytometry or fluorescence microscopy.
[0607] Example 7
[0608] CircRNA analysis
[0609] To measure the ratio of circular RNA to linear RNA, primers circGFPr (GAAGTTCTGCGACTGCACAC; SEQ ID NO: 41) and circGFPf (GCATGGACGAGCTGTACAAG; SEQ ID NO: 40) or circGFPr (GAAGTTCTGCGACTGCACAC; SEQ ID NO: 41) and circIntronf (GTGTTAGCAGCACAGATCAC; SEQ ID NO: 42) were used to amplify a small fragment in circRNA (a 176 bp fragment, specific for circular RNA) or a fragment including circ5Intron (a 194 bp fragment, specific for linear RNA) ( Figure 5 The following PCR conditions were applied: 95°C for 10 min, 95°C for 15 s, 60°C for 60 s, for 40 cycles. To quantify the absolute copy number of linear and circular RNAs, the same primer pairs were used in the EvaGreenDigital PCR Supermix (BIO-RAD) reaction according to the manufacturer's recommendations.
[0610] Sequence of sequence listing:
[0611]
[0612]
[0613] SEQ ID NO: 45 to SEQ ID NO: 185 see above
[0614] woDBD = no DNA binding domain
[0615] AS = amino acid
[0616] If a polynucleotide is defined above by its DNA nucleotide sequence, a polynucleotide defined by its RNA nucleotide sequence is also included, and vice versa.
Claims
1. A (linear) polynucleotide (capable of circularization), comprising, from 5' to 3', in the following order: The first back-splicing intron sequence, The first part of the RNA motif is recruited, The nucleotide sequence of interest, recruits the second part of the RNA motif, and The second back-splicing intron sequence, Wherein, the first part of the recruiting RNA motif and the second part of the recruiting RNA motif form a functional recruiting RNA motif after cyclization.
2. The polynucleotide according to claim 1, wherein The polynucleotide includes an internal ribosome entry site (IRES) or N6-methyladenosine (m6a) for translation initiation between the first portion of the recruiting RNA motif and the nucleotide sequence of interest.
3. The polynucleotide according to claim 1 or claim 2, wherein The polynucleotide comprises a promoter at the 5' end and / or a poly A tail at the 3' end.
4. The polynucleotide according to any one of claims 1 to 3, wherein The back-splicing intron is the ZKSCAN1 intron.
5. The polynucleotide according to any one of claims 1 to 4, wherein The circularization of the (linear) polynucleotide into a circular polynucleotide can be achieved by protein-assisted back-splicing or autocatalytic back-splicing.
6. The polynucleotide according to any one of claims 1 to 5, wherein The polynucleotide does not contain an in-frame stop codon to enable rolling circle translation after circularization.
7. The polynucleotide according to any one of claims 1 to 6, wherein The recruitment RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
8. The polynucleotide according to any one of claims 1 to 7, wherein The polynucleotide is a DNA polynucleotide or an RNA polynucleotide. 9 . A vector comprising the polynucleotide according to claim 1 .
10. An artificial circular RNA molecule comprising an RNA element of interest and a recruiting RNA motif.
11. The artificial circular RNA molecule according to claim 10, wherein The recruitment RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
12. The artificial circular RNA molecule according to claim 11, wherein The recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, or nucleotide sequences transcribed therefrom, and nucleotide sequences having at least 80% sequence identity therewith.
13. The artificial circular RNA molecule according to any one of claims 10 to 12, wherein The RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
14. A composite comprising: (i) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, and (ii) an artificial circular RNA molecule comprising an RNA element of interest, preferably the artificial circular RNA molecule according to any one of claims 10 to 13.
15. The composite according to claim 14, wherein The artificial circular RNA molecule comprises a recruitment RNA motif.
16. The composite according to claim 15, wherein The at least one RNA binding domain binds to the recruitment RNA motif.
17. The composite according to any one of claims 14 to 16, wherein The at least one RNA binding domain is connected / fused / linked to the viral capsid protein or a fragment or derivative thereof having the function of a capsid protein, preferably connected / fused / linked via a linker.
18. The composite according to claim 17, wherein The at least one RNA binding domain is connected / fused / linked to the N-terminus and / or C-terminus of the viral capsid protein or its fragment or derivative having capsid protein function, preferably connected / fused / linked via a linker.
19. The composite according to any one of claims 14 to 18, wherein The at least one RNA binding domain is a naturally occurring RNA binding domain or an artificial RNA binding domain.
20. The composite according to any one of claims 14 to 19, wherein The at least one RNA binding domain is selected from the group consisting of MS2 coat protein or its RNA binding portion, Ku protein or its RNA binding portion, Sm7 protein or its RNA binding portion, SfMu phage COM RNA binding protein or its RNA binding portion and PP7 coat protein or its RNA binding portion.
21. The composite according to any one of claims 15 to 20, wherein The recruitment RNA motif is selected from the group consisting of MS2 phage operator stem-loop, telomerase Ku binding motif, telomerase Sm7 binding motif, SfMu phage COM stem-loop and PP7 phage operator stem-loop.
22. The composite according to any one of claims 14 to 21, wherein (i) the at least one RNA binding domain is an MS2 coat protein or an RNA binding portion thereof, and the recruiting RNA motif is an MS2 bacteriophage operator stem-loop, (ii) the at least one RNA binding domain is a Ku protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Ku binding motif, (iii) the at least one RNA binding domain is a Sm7 protein or an RNA binding portion thereof, and the recruiting RNA motif is a telomerase Sm7 binding motif, (iv) the at least one RNA binding domain is a SfMu bacteriophage COM RNA binding protein or an RNA binding portion thereof, and the recruitment RNA motif is a SfMu bacteriophage COM stem-loop, and / or (v) the at least one RNA binding domain is a PP7 coat protein or an RNA binding portion thereof, and the recruitment RNA motif is a PP7 bacteriophage operator stem-loop.
23. The composite according to any one of claims 20 to 22, wherein The at least one RNA binding domain has an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and amino acid sequences having at least 80% sequence identity thereto.
24. The composite according to any one of claims 21 to 23, wherein The recruiting RNA motif has a nucleotide sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, or nucleotide sequences transcribed therefrom, and nucleotide sequences having at least 80% sequence identity therewith.
25. The composite according to any one of claims 14 to 24, wherein The RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
26. The composite according to any one of claims 14 to 25, wherein The virus is a DNA virus or an RNA virus.
27. The composite according to claim 26, wherein The DNA virus is selected from the group consisting of papovavirus, papillomavirus, polyomavirus, adenovirus and parvovirus, or The RNA virus is a retrovirus, norovirus or orthomyxovirus.
28. The composite according to claim 27, wherein The polyomavirus is Simian virus 40 (SV40), BK virus (BKV), JC virus (JCV) or MPy virus (MPyV), The parvovirus is an adeno-associated virus (AAV), The retrovirus is a lentivirus, The norovirus is Norwalk virus, or The orthomyxovirus is an influenza A virus or an influenza B virus.
29. The composite according to any one of claims 14 to 28, wherein The capsid protein is a capsid protein of an RNA virus or a DNA virus.
30. The composite according to claim 29, wherein The capsid protein of the DNA virus is selected from the group consisting of the capsid protein of papovavirus, the capsid protein of papillomavirus, the capsid protein of polyomavirus, the capsid protein of adenovirus and the capsid protein of parvovirus, or The capsid protein of the RNA virus is a capsid protein of a lentivirus.
31. The composite according to claim 30, wherein (i) the parvovirus capsid protein is an adeno-associated virus capsid protein, preferably an AAV9 capsid protein, (ii) the polyomavirus capsid protein is SV40 capsid protein, BKV capsid protein, JCV capsid protein or MPyV capsid protein, or (iii) The capsid protein of the lentivirus is a nucleocapsid (NC) protein, a matrix protein (MA) or a capsid protein (CA).
32. The composite according to claim 31, wherein (i) the AAV9 capsid protein is AAV9 VP1 capsid protein, AAV9 VP2 capsid protein or AAV9 VP3 capsid protein, (ii) the SV40 capsid protein is SV40 VP1 capsid protein, SV40 VP2 capsid protein or SV40 VP3 capsid protein, (iii) the BKV capsid protein is BKV VP1 capsid protein, BKV VP2 capsid protein or BKV VP3 capsid protein, (iv) the JCV capsid protein is JCV VP1 capsid protein, JCV VP2 capsid protein or JCV VP3 capsid protein, or (v) The MPyV capsid protein is MPyV VP1 capsid protein, MPyV VP2 capsid protein or MPyV VP3 capsid protein.
33. A complex according to claim 31 or claim 32, wherein The SV40 VP1 capsid protein has an amino acid sequence according to SEQ ID NO: 1 or an amino acid sequence having at least 80% sequence identity thereto, The SV40 VP2 capsid protein has an amino acid sequence according to SEQ ID NO: 2 or an amino acid sequence having at least 80% sequence identity thereto, The SV40 VP2 capsid protein without a DNA binding domain (woDBD) has an amino acid sequence according to SEQ ID NO: 3 or an amino acid sequence having at least 80% sequence identity thereto, The SV40 VP3 capsid protein has an amino acid sequence according to SEQ ID NO: 4 or an amino acid sequence having at least 80% sequence identity thereto, The nucleocapsid (NC) protein has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80% sequence identity thereto, The matrix protein (MA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80% sequence identity thereto, or The capsid protein (CA) has an amino acid sequence encompassed by the amino acid sequence according to SEQ ID NO: 31 or an amino acid sequence having at least 80% sequence identity thereto.
34. A virus-like particle (VLP), comprising the complex of any one of claims 14 to 33.
35. A virus-like particle (VLP) comprising an artificial circular RNA molecule comprising an RNA element of interest.
36. The VLP of claim 35, wherein The artificial circular RNA molecule is encapsidated in the VLP.
37. The VLP of claim 35 or claim 36, wherein The VLP comprises the complex of any one of claims 14 to claim 33.
38. The VLP of any one of claims 34 to 37, wherein The VLP is a DNA VLP or an RNA VLP.
39. The VLP of claim 38, wherein The DNA VLP is a VLP of a virus selected from the group consisting of papovavirus, papillomavirus, polyomavirus, adenovirus and parvovirus, or The RNA VLP is a VLP of a retrovirus, a norovirus or an orthomyxovirus.
40. The VLP of claim 39, wherein The polyomavirus is Simian virus 40 (SV40), BK virus (BKV), JC virus (JCV) or MPy virus (MPyV), The parvovirus is an adeno-associated virus (AAV), The retrovirus is a lentivirus, The norovirus is Norwalk virus, or The orthomyxovirus is an influenza A virus or an influenza B virus.
41. A method for producing a virus-like particle (VLP), the virus-like particle comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in any one of claims 34 to claim 40, the method comprising the following steps: (i) providing cells, and (ii) introducing the following into a cell, thereby producing the virus-like particle (VLP), wherein the virus-like particle includes an artificial circular RNA molecule comprising an RNA element of interest: (iia) a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide, and (iib) the polynucleotide according to any one of claims 1 to 8, the vector according to claim 9, the artificial circular RNA molecule comprising an RNA element of interest, or the artificial circular RNA molecule according to any one of claims 10 to 13.
42. A method for producing a virus-like particle (VLP), comprising an artificial circular RNA molecule comprising an RNA element of interest, preferably as defined in any one of claims 34 to claim 40, comprising the following steps: (i) providing a virus-like particle (VLP), wherein the virus-like particle comprises a polypeptide, wherein the polypeptide comprises a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, (ii) disassembling the VLPs, (iii) adding an artificial circular RNA molecule comprising an RNA element of interest or an artificial circular RNA molecule according to any one of claims 10 to 13, (iv) reassembling the disassembled VLPs, Thereby, the virus-like particle (VLP) is produced, which includes the artificial circular RNA molecule containing the RNA element of interest.
43. The method of claim 42, wherein: The virus-like particle (VLP) comprising a polypeptide comprising a capsid protein of a virus and at least one RNA binding domain provided in (i) is produced by: (a) providing cells, and (b) introducing a polypeptide comprising a viral capsid protein or a fragment or derivative thereof having the function of a capsid protein and at least one RNA binding domain, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide into the cell.
44. A method according to claim 42 or claim 43, wherein: The disassembly is achieved by chemical means.
45. The method of claim 44, wherein: The chemical means is selected from the group consisting of treatment with a reducing agent, preferably dithiothreitol (DTT), N-acetylcysteine (NALC), β-mercaptoethanol, tris(2-carboxyethyl)phosphine hydrochloride (TCEP) or thioredoxin.
46. The method according to any one of claims 41 to 45, wherein: The cell is a eukaryotic cell.
47. The method of claim 46, wherein: The eukaryotic cell is a vertebrate cell, an arthropod cell, a yeast cell or a fungal cell.
48. The method of claim 47, wherein: The vertebrate cell is a mammalian cell or the arthropod cell is an insect cell.
49. The method according to any one of claims 41 to 48, wherein: The RNA element of interest is selected from the group consisting of shRNA, miRNA, protein-coding RNA, pre-miRNA, piRNA, RNA complementary to other non-coding RNA, and ribozymes.
50. A virus-like particle (VLP), which is obtainable by the method of any one of claims 41 to 49.
51. A composition comprising the virus-like particle of any one of claims 34 to 40 or claim 50.
52. The composition according to claim 51, wherein The composition is a pharmaceutical composition.
53. The composition according to claim 52, wherein The pharmaceutical composition includes one or more pharmaceutically acceptable carriers.
54. A virus-like particle according to any one of claims 34 to 40 or claim 50 or a composition according to any one of claims 51 to 53 for use in medicine.
55. A virus-like particle according to any one of claims 34 to 40 or claim 50 or a composition according to any one of claims 51 to 53 for use in therapy.
56. A virus-like particle according to any one of claims 34 to 40 or claim 50 or a composition according to any one of claims 51 to 53 for use in vaccination.
